Full title:

LAMP-coupled CRISPR-Cas12a assays for upgrading molecular detection of *Leishmania* infections

Short title:

LAMP-CRISPR mediated *Leishmania* detection

Eva Dueñas[1,#a¶], Ingrid Tirado[1,2¶], Percy Huaihua[3], Ariana Parra del Riego[1], Luis Cabrera-Sosa[1,4,#b], Jose A. Nakamoto[1,#c], María Cruz[5], Carlos M. Restrepo[6], Jorge Arévalo[3,4], Vanessa Adaui[1,4*]

[1] Laboratory of Biomolecules, Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru; [2] Facultad de Ciencias Biológicas, Universidad Nacional Mayor de San Marcos, Lima, Peru; [3] Laboratorio de Patho-antígenos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru; [4] Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; [5] Facultad de Ciencias de la Salud, Universidad Andina del Cusco, Cusco, Peru; [6] Centro de Biología Molecular y Celular de Enfermedades, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Panama City, Panama

[#a]Current Address: Life Science Research Centre, Faculty of Science, University of Ostrava, Ostrava, Czech Republic

[#b]Current Address: Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium

[#c]Current Address: Laboratory of Protein Evolution, Department of Experimental Medical Science, Lund University, Lund, Sweden

*Corresponding author: vanessa.adaui@upc.pe (VA)

¶These authors contributed equally to this work.

Keywords: leishmaniasis, *Leishmania*, CRISPR-Cas, nucleic acid detection, isothermal amplification, LAMP, kDNA, 18S rDNA

Abstract

Background: Tegumentary leishmaniasis is a parasitic disease endemic in the Americas. Its clinical management and control rely on early and accurate diagnosis and adequate treatment. PCR-based molecular diagnostics offer high sensitivity and specificity over microscopy or culture but are less accessible in low-resource settings. New molecular tools for detecting *Leishmania* infections are needed in rural endemic regions. A promising tool harnessing CRISPR-Cas technology enables highly specific and sensitive detection of nucleic acid targets, offering an exciting potential for portable molecular diagnostics. Previously, we developed CRISPR-Cas12a-based assays coupled to PCR preamplification for *Leishmania* detection. Here, we adapted our assays, which target the 18S rDNA and kinetoplast DNA (kDNA) minicircles, by replacing PCR with loop-mediated isothermal amplification (LAMP).

Methodology/Principal Findings: LAMP-CRISPR assays were optimized for fluorescence-based and lateral flow readouts. The assays could detect as low as 0.2 genome equivalents per reaction using *L. braziliensis* M2904 strain genomic DNA. The kDNA assay reliably detected all tested species of the *Leishmania* (*Viannia*) subgenus, while the 18S assay showed pan-*Leishmania* detection capability. There was no cross-reactivity with other protozoan (*Trypanosoma cruzi* and *Plasmodium falciparum*) and bacterial (*Mycobacterium tuberculosis*) pathogen DNA, or with human DNA. When applied to 90 clinical samples (skin lesions) from the Cusco region of Peru and compared to kDNA real-time PCR, LAMP-CRISPR assays with a fluorescence readout achieved a sensitivity of 90.9% for kDNA and 72.7% for 18S rDNA, both with 100% specificity. Overall, lateral flow strip results agreed with fluorescence-based detection in 18 tested samples, with one discrepancy observed in the 18S assay associated with low parasite load.

Conclusions/Significance: These new assays, being amenable to further simplification and optimization for their adoption in low-resource settings, hold promise as a new generation of accurate molecular tools for leishmaniasis diagnosis and surveillance, supporting One Health strategies for disease control.

Author Summary

Tegumentary leishmaniasis affects poverty-related populations in the Americas and encompasses skin and mucosal lesions that can cause disfigurement and social stigma. The disease is caused by several species of the protozoan parasite *Leishmania*. PCR-based molecular diagnostics are currently the most sensitive and specific diagnostic tools. Yet, these require specialized infrastructure and trained personnel that are not readily available in low-resource settings. New tools are required to meet the diagnostic needs in rural endemic areas. A promising tool leveraging CRISPR-Cas technology enables cost-effective, *in vitro* nucleic acid detection, paving the way for diagnostic solutions that could be made available to patients at, or near, the point of care. Here, we harnessed the CRISPR-Cas12a system combined with loop-mediated isothermal amplification (LAMP) to develop assays capable of detecting multiple *Leishmania* species of medical importance. Our assays employ multi-copy targets widely used in molecular diagnostics: the 18S rDNA for pan-*Leishmania* detection and a kDNA minicircle region conserved among *L.* (*Viannia*) species. Results can be read with either fluorescence detection or lateral flow strips. Both assays showed satisfying performance in both analytical validation and clinical sample testing under laboratory conditions. These new tools show promise to improve diagnosis and surveillance of leishmaniasis.

85 ## Introduction

86 Leishmaniasis is one of the most serious neglected infectious diseases, with 0.7 to 1
87 million new cases each year and between 20,000 and 30,000 deaths [1, 2]. As a vector-
88 borne disease, leishmaniasis poses a substantial threat to millions of individuals in regions
89 where the disease is endemic, which include Asia, South and Central America, Africa and
90 the Mediterranean basin [3]. Leishmaniasis results from an infection with protozoan
91 parasites of the genus *Leishmania* that are transmitted to humans (and other mammals)
92 through the bite of infected sandflies and manifests in two main clinical forms: cutaneous
93 (or tegumentary) and visceral leishmaniasis, each presenting unique challenges in terms
94 of diagnosis, treatment, and control [4, 5]. In the Americas, tegumentary leishmaniasis is
95 widely distributed in 18 endemic countries and comprises a spectrum of clinical
96 conditions ranging from localized skin ulcers to severe disfiguring mucosal lesions [5].
97 This clinical pleomorphism is largely dependent on the immune responses of the human
98 host as well as on factors intrinsic to the different infecting *Leishmania* species [6].
99 Diverse *Leishmania* species from the *Viannia* and *Leishmania* subgenera circulate in
100 several Central and South American countries, with the former being responsible for the
101 majority of leishmaniasis cases [4]. While efforts directed toward the development of
102 effective prophylactic and therapeutic vaccines against human leishmaniasis are ongoing,
103 early and accurate diagnosis paired with timely chemotherapy remain the most vital tools
104 in the fight against the leishmaniases [7].

105 The diagnostic tools currently available for the detection of *Leishmania* spp.
106 infections include direct smear examination (light microscopy), *in vitro* culture,
107 immunological and molecular techniques [8]. Among the nucleic acid amplification
108 techniques (NAATs), the polymerase chain reaction (PCR) and its variants, such as real-
109 time PCR, currently provide the most sensitive and specific diagnostic tools available,

110 and several assays have been developed for the detection and identification of *Leishmania*
111 species [9, 10]. While accessible in research and reference laboratories, PCR-based
112 methods may not be readily available in rural endemic areas since they require
113 infrastructure, resources, and technical expertise [11]. Because of this, (near) point-of-
114 care (PoC) diagnostic tests have become a noteworthy concept, as they would allow
115 easier, faster and less expensive diagnostic alternatives that need only minimal laboratory
116 setup [12]. Advancements towards simplifying molecular diagnostic tools gave rise to
117 multiple isothermal NAATs, such as loop-mediated isothermal amplification (LAMP)
118 and recombinase polymerase amplification (RPA), which hold potential to decentralize
119 molecular diagnostic testing [13]. Of these, LAMP has gained prominence due to its
120 simplicity and effectiveness in detecting nucleic acid sequences with high specificity.
121 LAMP is different from the traditional PCR as it operates at a constant temperature (60-
122 65°C), eliminating the need for complex thermal cycling equipment [14, 15]. The LAMP
123 reaction uses 4 to 6 primers that target specific DNA sequences, along with the Bst DNA
124 polymerase, an enzyme that displays a strong strand displacement activity [14]. LAMP
125 amplifies the target DNA producing a concatenated DNA product with stem-loop DNA
126 structures, yielding up to 10^9 copies in less than an hour [14]. The results can be easily
127 visualized, e.g. on the basis of the turbidity caused by reaction by-products [16], or with
128 the use of sequence-specific probes [17, 18]. Due to its user-friendly nature and rapidity,
129 LAMP holds great promise as a tool for the diagnosis of infectious diseases in resource-
130 limited settings [19]. Several studies have reported LAMP assays for genus-, complex-
131 or species-specific detection of *Leishmania*; these achieved high sensitivity and
132 specificity and showed good diagnostic performance for human cutaneous leishmaniasis
133 (CL) and visceral leishmaniasis (VL) (reviewed in [20, 21]). A commercially available
134 LAMP kit (Loopamp™ *Leishmania* Detection Kit, developed by Eiken Chemical, Japan)

135 to detect *Leishmania* DNA has also been evaluated for the diagnosis of human CL and
136 VL and showed comparable performance to PCR-based methods [22].

137 Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
138 associated proteins (Cas) technology has recently been harnessed as a tool for molecular
139 detection and the development of CRISPR-based diagnostics [23], based on the discovery
140 that once Cas12a and Cas13a enzymes bound to CRISPR RNA (crRNA) recognize
141 specific nucleic acid targets, they become activated, thereby catalyzing cleavage of both
142 the targets (*cis*-cleavage) as well as non-target nucleic acids (*trans*-cleavage) [24, 25].
143 This collateral *trans*-cleavage activity can be applied for nucleic acid detection by
144 coupling it with a reporter molecule. For fluorescence-based assays, the reporter molecule
145 consists of a DNA or RNA oligomer carrying a fluorophore and a quencher. So, upon
146 target recognition, reporter cleavage by the activated Cas enzyme generates a detectable
147 fluorescence signal that indicates that the target nucleic acid sequence is present in a
148 sample. Alternatively, visualization of the Cas detection reaction can be achieved by a
149 lateral flow strip readout using a reporter molecule labeled with FAM or digoxin and
150 biotin [26, 27]. CRISPR-based assay platforms reported thus far enable a highly sensitive
151 detection of nucleic acids in the attomolar range when combined with a target
152 preamplification step using either isothermal NAATs (e.g. DETECTR [24] and
153 SHERLOCK [25]) or PCR-based NAATs (e.g. HOLMES [28]). Notwithstanding that this
154 two-step CRISPR-based assay format increases assay complexity and poses the risk of
155 cross-contamination during sample transfer to the CRISPR reaction, it is a convenient
156 way to pursue in the first development phase of CRISPR-based assays to demonstrate
157 their potential for further assay development [29]. More recent efforts aim for
158 amplification-free detection of nucleic acid targets with CRISPR, and the proof-of-

159 concept was demonstrated for direct detection of pathogen RNA and DNA with
160 quantitative ability [30-33].

161 The combination of CRISPR-Cas and LAMP technologies has advanced the
162 progress of nucleic acid-based PoC diagnostic test development. Coupling LAMP
163 reactions to downstream CRISPR-based detection improves specificity [19, 23], since
164 LAMP is prone to non-specific amplification [34]. Integrated LAMP-CRISPR assays
165 have been developed for the detection of several pathogens, including viruses (e.g. SARS-
166 CoV-2 [26, 35-37], human papillomavirus [38]), bacteria (e.g. *Mycobacterium*
167 *tuberculosis* [39], *Klebsiella pneumoniae* [40]), and fungi (e.g. *Verticillium dahliae* [41]).
168 CRISPR-based assays have also been developed for the detection of parasites of medical
169 and veterinary importance, such as the protozoa *Plasmodium* spp. [29, 42], *Toxoplasma*
170 *gondii* [43], *Leishmania* spp. [44-47], *Trypanosoma brucei* [48, 49], and *Trypanosoma*
171 *cruzi* [50]; and the trematode *Schistosoma* species [51, 52]. These assays, aiming at
172 sensing parasite nucleic acid sequences in biological specimens, mostly combined
173 CRISPR with RPA preamplification. Applications of LAMP-CRISPR for parasite
174 detection are increasing, as illustrated by the detection of *Schistosoma* infection in host
175 samples [53], the *in silico* design of LAMP primers and Cas12a crRNA sequences for
176 identifying genetic polymorphisms associated with drug resistance in *P. falciparum*
177 infections [54], the detection of *T. gondii* in environmental samples [55], and the detection
178 of *T. cruzi* in infants for diagnosing acute congenital infection [56].

179 At present, leishmaniasis diagnosis in endemic areas is impaired mainly by the
180 lack of infrastructure, equipment, trained human resources, and low access (if any) to
181 effective diagnostic tools. New molecular diagnostic tools that are accurate, easy to use,
182 accessible and affordable for use in resource-limited settings are required. In previous
183 work, we developed CRISPR-Cas12a-based assays coupled to PCR preamplification for

184 detection of *Leishmania* spp. in clinical samples [45]. Here, we have adapted our assays,
185 which target the *Leishmania* 18S ribosomal RNA gene (18S rDNA) and minicircle
186 kinetoplast DNA (kDNA), by replacing PCR with LAMP in the preamplification step, to
187 facilitate the road towards the development of a nucleic acid-based near-PoC diagnostic
188 tool for leishmaniasis. We optimized LAMP-CRISPR assay conditions with a
189 fluorescence signal readout in a plate reader as well as a visual readout on lateral flow
190 strips. We report the evaluation of LAMP-CRISPR assay diagnostic performance against
191 a kDNA real-time PCR assay on stored clinical samples from the Cusco region, a highly
192 endemic area for tegumentary leishmaniasis in south-central Peru where *Leishmania*
193 species of the *Viannia* subgenus circulate [57, 58].
194

195 ## Methods

196

197 **DNA samples from reference strains of *Leishmania* and other microbial pathogens**
198 Genomic DNA (gDNA) samples extracted from cultured promastigotes of reference
199 strains of *Leishmania* spp. analyzed here were retrieved from the DNA biobank of the
200 *Leishmania* research group at the Molecular Epidemiology Unit of the Instituto de
201 Medicina Tropical Alexander von Humboldt (IMTAvH), Universidad Peruana Cayetano
202 Heredia (UPCH) in Lima, Peru, and from the collection hosted by the Institute for
203 Scientific Research and High Technology Services (INDICASAT-AIP) in Panama.
204 gDNA samples isolated from cultured laboratory reference strains of other microbial
205 pathogens (*Trypanosoma cruzi*, *Plasmodium falciparum*, *Mycobacterium tuberculosis*)
206 were provided by the Infectious Diseases Research Laboratory at the UPCH and
207 INDICASAT-AIP. The designation and source of the strains whose gDNA were analyzed
208 in this study are listed in Table 1.

209 At the IMTAvH and UPCH, DNA was isolated using the High Pure PCR
210 Template Preparation Kit (Roche, Mannheim, Germany). At the INDICASAT-AIP, the
211 Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA) was used. DNA
212 was isolated according to the manufacturer's protocol, suspended in elution buffer or TE
213 buffer and stored at -20°C until use.

214

215 **Table 1. Reference strains used in this work**.

Strain name	WHO code[¥]	Source
Leishmania (Viannia) braziliensis	MHOM/BR/75/M2904	IMTAvH-UPCH
Leishmania (Viannia) braziliensis	MHOM/BR/75/M2903	INDICASAT-AIP
Leishmania (Viannia) braziliensis	MHOM/PE/91/LC2043	IMTAvH-UPCH
Leishmania (Viannia) braziliensis	MHOM/PE/91/LC2177	IMTAvH-UPCH
Leishmania (Viannia) peruviana	MHOM/PE/90/HB86	IMTAvH-UPCH
Leishmania (Viannia) peruviana	MHOM/PE/90/LCA08	IMTAvH-UPCH
Leishmania (Viannia) peruviana	MHOM/PE/2005/WR-2771	INDICASAT-AIP
Leishmania (Viannia) guyanensis	MHOM/BR/1975/M4147	INDICASAT-AIP
Leishmania (Viannia) lainsoni	MHOM/BR/1981/M6426	INDICASAT-AIP
Leishmania (Viannia) panamensis	MHOM/PA/2018/BD-02	INDICASAT-AIP
Leishmania (Leishmania) amazonensis	MHOM/BR/1973/M2269	INDICASAT-AIP
Leishmania (Leishmania) mexicana	MHOM/BZ/1982/BEL21	INDICASAT-AIP
Leishmania (Leishmania) aristidesi	MORY/PA/1969/GML	INDICASAT-AIP
Leishmania (Leishmania) major	MHOM/SA/1991/WR-1088	INDICASAT-AIP
Leishmania (Leishmania) infantum	MCAN/BR/1997/P142	INDICASAT-AIP
Leishmania (Leishmania) donovani	MHOM/IN/2006/WR-2801	INDICASAT-AIP
Trypanosoma cruzi	Sylvio X10	UPCH
Trypanosoma cruzi	VT-1	UPCH
Trypanosoma cruzi	Tulahuen LacZ clone C4	UPCH
Plasmodium falciparum	HB3	INDICASAT-AIP
Mycobacterium tuberculosis	PA155-18C	INDICASAT-AIP

216

217 [¥]The World Health Organization (WHO) designation code for *Leishmania* strains is as follows: host (M
218 for Mammalia; HOM = *Homo sapiens*; CAN = *Canis familiaris*; ORY = *Oryzomys capito*)/country of
219 origin (BR = Brazil; BZ = Belize; IN = India; PA = Panama; PE = Peru; SA = Saudi Arabia)/year of
220 isolation/name of strain.

221

222

223 **Patient DNA samples**

224 **Ethics statement**

225 This study used anonymized stored DNA samples that were assigned a code and had been
226 isolated from different human skin ulcerative lesion specimen types, including biopsy,
227 lancet scraping, cytological brush, swab, and filter paper. The respective patients had
228 provided written informed consent for future research use of their specimens and clinical
229 data. Patients with clinically suspected CL were recruited at the Hospital Nacional Adolfo
230 Guevara Velasco (HNAGV) in Cusco, a region in Peru with endemic circulation
231 of *Leishmania* (*Viannia*) parasites, most frequently *L. braziliensis*, *L. guyanensis* and *L.*
232 *lainsoni* [57, 58], as part of another study between the HNAGV and UPCH (contract 095-
233 2018-FONDECYT-BM-IADT-AV to JA, financed by CONCYTEC and The World
234 Bank). The study protocol and informed consent (registration number 103155) were
235 reviewed and approved by the ethics committee of the UPCH (IRB approval letter 063-
236 05-19 dated 01/30/2019, latest renewed on 05/02/2023 with letter R-149-17-23).

237 **DNA extraction from clinical samples prior to this study**

238 DNA from clinical samples was isolated with the High Pure PCR Template Preparation
239 Kit (Roche), according to the manufacturer's protocol, suspended in elution buffer and
240 stored at -20°C until use.

241

242 **LAMP primer design**

243 The 18S rDNA gene (TriTrypDB ID: LbrM.27.2.208540; at
244 https://tritrypdb.org/tritrypdb/) and kDNA minicircles (GenBank accession no.
245 KY698803.1) from *L. braziliensis* MHOM/BR/75/M2904 were selected for LAMP
246 primer design. FASTA sequences up to 200 bp downstream and upstream to previously
247 reported crRNA target recognition sites for each gene [45] were uploaded to

248 PrimerExplorer V5 software (Eiken Chemical Co., Ltd). Three sets of external (F3 and
249 B3) and internal (FIP and BIP) primers were obtained for 18S rDNA, but only one for
250 kDNA. To select the final 18S primer set, the following features were considered: the less
251 likelihood of primer dimer formation (highest ΔG value), the 3' end stability for F2 and
252 B2 (ΔG ≤ -4 kcal/mol), the 5' end stability for F1c and B1c (ΔG ≤ -4 kcal/mol) and the
253 less overlap between primers and the recognition site. After that, loop primers (LF and
254 LB) for both target genomic regions were also designed using the PrimerExplorer V5
255 software. Final primer sets were ordered from Macrogen Inc. (Seoul, South Korea) and
256 are listed in the S1 Table.

257 To investigate the *in silico* specificity of the designed LAMP primers, we
258 downloaded all publicly available DNA sequences for each target from NCBI in May
259 2025. For *Leishmania* kDNA minicircle sequence analysis, a total of 1,060 sequences
260 from the *L.* (*Viannia*) subgenus and 965 sequences from the *L.* (*Leishmania*) subgenus
261 were retained and analyzed following a quality filtering process. Sequences that were
262 excluded contained ambiguous base pairs (e.g. 'N') exceeding 10% of the total length or
263 did not cover the primer binding sites. The eight LAMP primer binding regions and the
264 crRNA target site were manually annotated using Jalview v2.11.4.1 [59] following
265 multiple sequence alignment with Clustal Omega [60]. Sequence alignments are available
266 in the S1 File. A representative subset of 59 sequences (24 *Viannia*, 35 *Leishmania*) is
267 illustrated in S1 Fig to indicate sequence conservation or variations across the two
268 analyzed *Leishmania* subgenera. As for the 18S rDNA, 37 sequences from *Leishmania*
269 spp. and 272 from *Trypanosoma* spp. were aligned and analyzed using the same
270 bioinformatics pipeline (S2 File). A subset of 31 representative sequences (16 *Leishmania*
271 spp., 15 *Trypanosoma* spp.) was selected to denote sequence conservation or variations
272 across the two analyzed trypanosomatid genera (S2 Fig).

273

274 **crRNA guide sequences and preparation**

275 We used previously reported LbCas12a crRNA guide sequences targeting 18S rDNA and
276 kDNA minicircle sequences [45]. crRNA preparation from double-stranded DNA
277 templates (see S1 Table for nucleotide sequences) was performed as described previously
278 [45].

279

280 **Loop-mediated isothermal amplification (LAMP) assay**

281 We first optimized the LAMP assay reaction conditions using a commercial Bst 2.0®
282 DNA polymerase (New England Biolabs Inc (NEB), Massachusetts, USA; Cat no.
283 M0537), following the LAMP protocol as suggested by the manufacturer (NEB). The
284 only modification was the final total concentration of $MgSO_4$ in the reaction (6 mM Mg^{2+}
285 for 18S rDNA and 5 mM Mg^{2+} for kDNA). These reaction conditions were used to
286 evaluate the incubation time needed for optimal amplification of the target DNA, which
287 was tested at 2×10^2, 2×10^{-1}, and 2×10^{-3} parasite genome equivalents (GE) per reaction
288 to cover a wide range of target abundance. The LAMP reaction products were analyzed
289 by 2% agarose gel electrophoresis using SYBR Gold staining and tested downstream
290 using CRISPR-Cas12a assays with fluorescence readout (see below).

291 To facilitate master mix preparation for sample processing, LAMP reactions for
292 the preamplification of *Leishmania* DNA targets were performed using the WarmStart®
293 LAMP Kit (DNA & RNA) (NEB; Cat no. E1700). Each reaction contained 12.5 µL of
294 WarmStart LAMP 2X Master Mix, 8 µL of molecular biology grade water, and 2.5 µL of
295 10X LAMP primer mix for a single target (kDNA or 18S rDNA). Like for the LAMP
296 protocol using the separate Bst enzyme, the six target-specific primers (3 sets) were added
297 at a final concentration of 1.6 µM for forward inner and backward inner primers

298 (FIP/BIP), 0.4 μM for loop forward and loop backward primers (LF/LB), and 0.2 μM for
299 forward external and backward external primers (F3/B3). After that, we carefully added
300 20 μL of immersion oil over the LAMP mix to create two layers to prevent cross
301 contamination. Then, 2 μL of DNA template (0.26 – 40 ng, for analytical testing) was
302 added to the first (bottom) layer, corresponding to the LAMP mixture, bringing the final
303 reaction volume to 25 μL. The LAMP reaction was incubated on a heating block at 65°C
304 for 30 min for kDNA or for 50 min for 18S rDNA, and then stopped by incubating at
305 82°C for 3 min.

306 A positive control (*L. braziliensis* M2904 gDNA, 10^2 – 10^4 GE as indicated in the
307 figure legends) and a negative amplification control (LAMP reaction without DNA
308 template, i.e., No-Template Control (NTC)) were included in all experiments. In the
309 analytical specificity testing, a negative control consisting of human gDNA from
310 peripheral blood mononuclear cells (PBMC) of a healthy donor (40 ng of input DNA)
311 was also included.

312

313 **CRISPR-Cas12a assay with fluorescence readout**

314 LbCas12a-based detection reactions were performed as described previously [45, 61, 62],
315 with the only modification being that a different reporter probe was used, which allows
316 fluorescence signal visualization on a LED transilluminator. We prepared the
317 ribonucleoprotein (RNP) complex 10X by mixing recombinant LbCas12a (produced in-
318 house [63]) with the target-specific folded crRNA (incubated at 65°C for 10 min followed
319 by room temperature (RT) incubation for 10 min) in a 1:1.5 molar ratio and 2 μM single-
320 stranded DNA (ssDNA) reporter probe (/56-FAM/TTATT/3IABkFQ/; [24]) in reaction
321 buffer 1X (NEBuffer 2.1 recipe, prepared in-house, without adding $MgCl_2$). The labeled
322 fluorophore/quencher probe was purchased from Macrogen Inc. (Seoul, South Korea). A

323 volume of 10 µL of the 10X RNP complex (pre-incubated for 10 min at RT) was loaded
324 into each well of a flat-bottom, black 96-well microplate (Thermo Fisher Scientific,
325 Waltham, MA, United States; Cat. no. 237107). Subsequently, 90 µL of the diluted
326 LAMP product –prepared by diluting 2 µL of the LAMP product in 106 µL of 1X reaction
327 buffer containing 16.7 mM $MgCl_2$– was added. The 100 µL LbCas12a *trans*-cleavage
328 reaction, with a final $MgCl_2$ concentration of 15 mM, was incubated and analyzed in a
329 fluorescence plate reader (Synergy™ H1 hybrid multi-mode reader; BioTek Instruments,
330 Winooski, VT, United States) for 121 min at 25°C. Fluorescence measurements were
331 recorded every 1 min (λex: 490 nm; λem: 525 nm) with a fluorescence gain setting of
332 120. For the experiments shown in S3 Fig, measurements used the Varioskan™ LUX
333 multimode microplate reader (Thermo Fisher Scientific).
334

335 **Optimization of the CRISPR-Cas12a-based detection assay coupled with lateral**
336 **flow readout**

337 The lateral flow assay (LFA) readout was optimized using the HybriDetect - Universal
338 lateral flow assay kit (Milenia Biotec GmbH, Giessen, Germany; Cat. no. MGHD 1)
339 according to the manufacturer's instructions. First, to optimize the reporter probe
340 concentration (for reducing the background signal on the T-line of the LFA strip in
341 negative controls), we tested the reporter at a final concentration (1X) of 500 nM, 250
342 nM, and 100 nM per LFA. Second, we tested the reaction buffer 1X without $MgCl_2$
343 (prepared in-house following the NEBuffer 2.1 recipe) as compared to the HybriDetect
344 universal assay buffer. Third, we tested two incubation temperatures of the Cas12a
345 reaction: either 25°C or 37°C, for a reaction time of 30 min or 60 min. Fourth, we
346 evaluated the addition of polyethylene glycol (PEG)-8000 at 2% and 4% final

347 concentration to the completed CRISPR-Cas12a reaction for increasing the viscosity of
348 the buffer, which in turn slows down lateral flow speed.
349
350 **Optimized CRISPR-Cas12a-based lateral flow strip assay for clinical samples and**
351 **reference strain genomic DNA**
352 After completion of the preamplification step, 2 µL of the LAMP product was mixed with
353 106 µL of 1X reaction buffer with 16.7 mM $MgCl_2$ in a 1.5 mL microcentrifuge tube.
354 Then, we took 90 µL of the diluted LAMP product in a new microcentrifuge tube and
355 added 10 µL of the 10X pre-incubated RNP complex (100 nM Cas12a: 150 nM crRNA:
356 1000 nM reporter probe). The lateral flow cleavage reporter probe (5'/Bio/TTATTATT/6-
357 FAM/3'; with terminal biotin and FAM labels in the opposite order relative to [26]) was
358 purchased as an HPLC-purified oligo from biomers.net GmbH (Ulm, Germany). The 100
359 µL LbCas12a *trans*-cleavage reaction, with a final $MgCl_2$ concentration of 15 mM, was
360 incubated at 37°C for 60 min in the dark. Afterward, 5 µL of PEG-8000 (2% final
361 concentration) was added to the reaction tube and homogenized by pipetting up and down.
362 A lateral flow strip (Milenia HybriDetect) was placed into the reaction tube and incubated
363 for 5 min at RT. Lateral flow strips were interpreted visually. LFA strip images shown
364 here were taken with an iPhone 13 Pro camera.
365
366 **Analytical sensitivity testing**
367 Serial dilutions of *L. braziliensis* M2904 gDNA (extracted from a promastigote culture)
368 to a final range of 2×10^4 to 2×10^{-3} parasite GE per reaction (encompassing the same
369 range of parasite GE per reaction of the standard curve used in the kDNA qPCR assay
370 [64]) were tested as input DNA in LAMP reactions to amplify the target gene, followed
371 by LbCas12a-based detection assays as described above, using a plate-based fluorescence

372 readout and a colorimetric lateral flow-based readout. The analytical sensitivity for each
373 target gene was determined based on 3 independent experiments.
374
375 **Analytical specificity testing**
376 The analytical specificity of the LAMP-CRISPR assays targeting *Leishmania* kDNA
377 (*Viannia* subgenus) or 18S rDNA was tested using gDNA from representative laboratory
378 reference strains of New World and Old World *Leishmania* species, as well as other
379 microbial pathogens (Table 1). Target genes were amplified by LAMP (using 20–40 ng
380 of input DNA) and detected by LbCas12a-based detection assays as described above,
381 using fluorescence-based and lateral flow-based readouts. Two independent LAMP-
382 CRISPR experiments were performed.
383
384 **Evaluation of LAMP-CRISPR assay performance on clinical samples**
385 Patient DNA samples extracted from skin lesion specimens were tested blindly by the
386 LAMP-CRISPR assays in groups of ten, plus positive and negative controls. The DNA
387 input for the LAMP preamplification step was 5 µL of diluted or undiluted DNA samples
388 (6–285 ng of input DNA; see S1 Dataset) to capture data from samples with low
389 *Leishmania* parasite load levels. The LAMP products were then detected by LbCas12a-
390 based detection assays as described above.
391
392 **Quantitative real-time PCR (qPCR)**
393 A qPCR assay targeting *Leishmania* kDNA minicircles was performed to detect and
394 quantify *Leishmania* (*Viannia*) parasites in clinical samples, using primers and cycling
395 conditions as described [64]. The human *ERV-3* gene was amplified in parallel using the
396 primers reported by Yuan *et al*. [65]; it served as an indicator of specimen adequacy and

397 to estimate the parasite load normalized to the number of human cell equivalents per
398 sample [64].
399
400 **Data processing and analysis**
401 The data collected from LAMP-CRISPR assays were analyzed as described previously
402 [45]. Briefly, the raw fluorescence data from each well of the LbCas12a-based assay plate
403 were exported to Microsoft Excel. Based on the inspection of fluorescence time-course
404 data from samples and controls that were run in parallel, the time point of fluorescence
405 accumulation for data analysis was defined (at 25-min time point for both kDNA and 18S
406 rDNA). The raw fluorescence data were normalized by dividing target reaction
407 fluorescence accumulated at the defined time point of the test sample to that of the NTC
408 reaction included in parallel in the same Cas12a assay plate (further called 'fluorescence
409 ratio'). In the analytical validation, a result was considered 'detected' if a target reaction
410 produced a fluorescence ratio ≥ 2 for the test sample above background (NTC). To set a
411 threshold cutoff value for positive signal (i.e., detection of *Leishmania*) in clinical
412 samples, we required that the fluorescence ratio be larger than the mean and three standard
413 deviations of negative clinical samples (see S1 Dataset) selected as a separate panel for
414 determining the cutoff. Graphs, numerical data analyses, and statistical analyses were
415 performed using GraphPad Prism version 10.2 (GraphPad Software, San Diego, CA,
416 United States).
417 For the diagnostic performance evaluation of the LAMP-CRISPR assays with
418 fluorescence readout, the sensitivity and specificity and their 95% confidence intervals
419 were calculated with MedCalc software [66] using kDNA real-time PCR as the reference
420 test. To evaluate the accuracy of the LAMP-CRISPR assays to discriminate a positive
421 (detected) from a negative (not detected) *Leishmania* infection status, a receiver operating

422 characteristic (ROC) curve was drawn and the area under the curve (AUC) with its 95%
423 confidence interval was calculated using GraphPad Prism version 10.2. In all statistical
424 tests, a P value of < 0.05 was considered statistically significant.

425 To assess the applicability of the LAMP-CRISPR assays with an LFA readout, 18
426 clinical samples selected for pilot testing were arbitrarily categorized into three groups
427 based on parasite load: low (<100 parasites/10^6 human cells), intermediate (100 – 10,000
428 parasites/10^6 human cells), and high (>10,000 parasites/10^6 human cells). LFA strips were
429 interpreted blinded to the fluorescence results.

430

431 # Results

432 **Design and optimization of LAMP-CRISPR assays**

433 We developed two assays for the detection of *Leishmania* spp., which are based on the
434 most frequently used multicopy genetic markers in molecular diagnostics for
435 leishmaniasis: kDNA minicircles and 18S rDNA. Our assays combine LAMP with
436 CRISPR-LbCas12a-mediated DNA target recognition and ssDNA reporter cleavage, with
437 results assessed either with a fluorescence-based or lateral flow strip readout (Fig 1).
438 These two readouts are made possible through the use of different dual-labeled ssDNA
439 reporter molecules: one labeled with a fluorophore-quencher pair for real-time monitoring
440 of fluorescence curves over the Cas12a reaction time course on a plate reader, and the
441 other labeled with biotin and FAM for results to be visually read with paper-based lateral
442 flow strips [26].

443

444

445 **Fig 1. Schematic representation of the workflow of LAMP-CRISPR assays for**
446 **detection of *Leishmania* spp. in clinical samples**. Sample preparation is performed from

447 skin lesion specimens taken from patients with suspected CL. The DNA samples are
448 subjected to LAMP amplification for just 30 min (kDNA) or 50 min (18S rDNA),
449 followed by Cas12a-based reactions with either a fluorescence-based or lateral flow strip
450 readout. Figure created with BioRender.com.
451
452
453 We designed LAMP primers flanking previously reported crRNA target
454 recognition sites [45] within *Leishmania* kDNA minicircles (S1 Fig) and 18S rDNA (S2
455 Fig). According to the *in silico* analyses, the kDNA primer set targets a region most
456 conserved within the *L*. (*Viannia*) subgenus and less conserved within the *L*. (*Leishmania*)
457 subgenus (S1 Fig and S1 File). *In silico* analysis of the selected 18S primer set showed
458 the expected conserved nature of the targeted genomic region at the *Leishmania* genus
459 level, whereas sequence variations were more frequent within the *Trypanosoma* genus
460 (S2 Fig and S2 File).
461 A schematic depicting the mechanism of LAMP amplification, with the resulting
462 LAMP amplicon containing the Cas12a crRNA target sequence is shown in Fig 2. We
463 optimized the LAMP assay reaction conditions using a commercial Bst 2.0 DNA
464 polymerase and tested the incubation time required for optimal amplification of the target
465 DNA. The CRISPR-Cas12a assay was used as the readout. For kDNA, the LAMP
466 reaction was evaluated at 4 different incubation times (10, 20, 30, and 40 min) (S3A-D
467 Fig). While 10 min were sufficient to amplify the target DNA sequence present at a high
468 quantity (2×10^2 GE) (S3A Fig), at least 20 min were required for the amplification of
469 low abundant target DNA (2×10^{-1} GE) (S3B Fig). On the other hand, an incubation time
470 of 40 min enabled the amplification of a very low quantity of the target DNA (2×10^{-3}
471 GE) but also resulted in a positive signal of the NTC reaction (S3D Fig), the latter

472 indicative of contamination. These results were corroborated through visualization of the
473 LAMP reaction products by agarose gel electrophoresis (S3F Fig). We thus chose an
474 incubation time of 30 min as the most optimal for the kDNA LAMP reaction (S3C and
475 S3E Fig) for further experiments. For the 18S rDNA gene, we tested the LAMP reaction
476 at 5 different incubation times (10, 30, 40, 50, and 60 min) (S3G-K Fig). At least 40 min
477 were required to amplify the target DNA present at varying levels of abundance (2×10^{2}
478 and 2×10^{-1} GE) (S3I Fig). Extending the incubation time of the LAMP reaction to 60
479 min allowed the amplification of very low-abundant target DNA (2×10^{-3} GE) but also
480 resulted in NTC contamination (1 out of 2 replicates of the NTC reaction showed a
481 positive signal) (S3K Fig). CRISPR-Cas12a-based detection of LAMP amplicons could
482 effectively discriminate between specific amplification products and non-specific
483 amplification. The latter was observed, for instance, at the incubation times of 10 min and
484 40 min in the NTC reaction by agarose gel electrophoresis (S3M Fig) but did not result
485 in false positives in the Cas12a assay (S3G and S3I Fig). On the basis of these results, we
486 selected an incubation time of 50 min for the 18S LAMP reaction (S3J and S3L Fig) for
487 further experiments.
488
489
490 **Fig 2. Schematic representation of the LAMP reaction, highlighting the location of**
491 **the crRNA target sequence in the target DNA**. (A-E) Steps in the LAMP reaction to
492 amplify the target DNA. The eight annealing locations of the six LAMP primers are
493 shown. The primers were designed to target unique sequences within a conserved region
494 of *Leishmania* kDNA minicircles (S1 Fig) or nuclear 18S rDNA (S2 Fig). The crRNA
495 target sequence and protospacer adjacent motif (PAM) site in the target DNA are shown.
496 For simplicity, the locations of both crRNA target sites are depicted in the same graph

497 (actually, the LAMP reaction is performed separately for each target). Figure adapted
498 from [14, 67] and created with BioRender.com.
499
500
501 The CRISPR-Cas12a assay is based on purified recombinant LbCas12a [63]. For
502 the fluorescence-based assay, we used optimized conditions as described previously [45,
503 61, 62] and a quenched fluorescent ssDNA reporter [24]. We optimized here the
504 performance of the Cas12a-based LFA readout by testing varying concentrations of the
505 biotin-FAM reporter probe as well as the influence of the assay buffer, incubation
506 temperature and reaction time of the Cas12a assay, and PEG-8000 addition. The optimal
507 conditions identified involved: using the reporter probe at a final concentration (1X) of
508 100 nM in our in-house Cas12a reaction buffer 1X (which performed comparable to the
509 HybriDetect universal assay buffer); incubating the Cas12a reaction at 37°C for 60 min;
510 and adding 2% PEG-8000 to the completed Cas12a reaction (S4 Fig).
511
512 **Analytical validation of LAMP-CRISPR assays**
513 We then assessed the analytical sensitivity of each primer set-crRNA combination using
514 serial dilutions of *L. braziliensis* M2904 gDNA extracted from a promastigote culture.
515 The kDNA LAMP-CRISPR assay displayed positive *L. braziliensis* detection down to 2
516 $\times 10^{-1}$ GE per reaction, both with a fluorescence readout (Fig 3A) and a LFA readout (Fig
517 3B). Visualization of the kDNA LAMP products on an agarose gel confirmed the
518 presence of ladder-like bands indicative of a successful LAMP reaction (Fig 3C),
519 consistent with the Cas12a-based detected amplicon samples (Fig 3A and 3B). We found
520 a similar analytical sensitivity for the 18S LAMP-CRISPR assay, as detection of at least
521 2×10^{-1} GE/reaction was achieved with a fluorescence-based readout (Fig 3D) and a LFA

522 readout (Fig 3E). The analysis of the 18S LAMP products by agarose gel electrophoresis
523 (Fig 3F) was consistent with the Cas12a assay results (Fig 3D and 3E). The no-template
524 control (NTC) tested in parallel in each LAMP-CRISPR assay showed a background
525 signal in the Cas12a fluorescence-based assay (Fig 3A and 3D, see the two lowest GE
526 input amounts whose fluorescence ratio is 1 given that the denominator is the NTC
527 signal). Likewise, the NTC did not exhibit a band (or the band observed was faint) at the
528 test line in the lateral flow strips (Fig 3B and 3E). This ruled out the possibility of cross-
529 contamination and non-specific amplification.
530
531
532 **Fig 3. Analytical sensitivity testing of kDNA and 18S LAMP-CRISPR assays**. Serial
533 dilutions of *L. braziliensis* M2904 gDNA encompassing 2×10^4 to 2×10^{-3} genome
534 equivalents (GE) per reaction were subjected to LAMP amplification, followed by
535 Cas12a-based reactions for the kDNA (A-C) or 18S rDNA (D-F) target. (A, D)
536 Normalized fluorescence signals (fluorescence ratio) from Cas12a reactions (i.e.,
537 fluorescence signals taken at t = 25 min in the test sample relative to the NTC).
538 Fluorescence measurements were taken on the Synergy H1 plate reader. Data are
539 represented as mean ± SD (n = 3 independent amplification and detection runs). The X-
540 axis has a logarithmic scale. A fluorescence ratio ≥ 2 is considered detected. (B, E) Cas12a
541 reactions were performed using a biotin-FAM reporter molecule and visualized on lateral
542 flow strips. Uncleaved reporter molecules are captured at the first detection line (control
543 line), whereas collateral Cas12a cleavage activity generates a signal at the second
544 detection line (test line). The arrow indicates the direction of flow. Two independent
545 amplification and detection runs (r1 and r2) were analyzed. (C, F) LAMP reaction
546 products (5 μL) visualized by 2% agarose gel electrophoresis ran at 100 V for 1 h using

547 SYBR Gold staining. L, GeneRuler 100 bp (C) or 100 bp Plus (F) DNA ladder. NC,
548 negative control (NTC, no-template control). Since space was tight on the agarose gel
549 images, we had to abbreviate the labels for each lane. For instance, "10^4" actually
550 represents "2×10^4" as indicated in the fluorescence (A, D) and LFA (B, E) panels.
551
552
553 Assay specificity testing (S5 Fig) was performed using gDNA samples isolated
554 from cultured laboratory reference strains of *Leishmania* spp., phylogenetically close
555 pathogens, and pathogens that cause similar lesions to CL or can coinfect the same host
556 (Table 1). The kDNA LAMP-CRISPR assay consistently detected representative strains
557 of the *Leishmania* (*Viannia*) species present in our sample set (10 of 10; Fig 4A). This
558 was expected given that our designed kDNA-crRNA targets a region of kDNA
559 minicircles conserved within the *L*. (*Viannia*) subgenus ([45] and S1 Fig). Additionally,
560 the assay detected 2 out of 6 tested strains belonging to the *L*. (*Leishmania*) subgenus (Fig
561 4A). The 18S LAMP-CRISPR assay showed pan-*Leishmania* detection ability (Fig 4A).
562 In both kDNA and 18S LAMP-CRISPR assays, no cross-reactivity was observed for
563 related trypanosomatid (*T. cruzi*) strains and other protozoan (*P. falciparum*) and bacterial
564 (*M. tuberculosis*) pathogens tested (Fig 4A). Also, the negative control with human
565 gDNA as template was not detected (Fig 4A). The analytical specificity was also assessed
566 with an LFA readout, where strips were interpreted by visual inspection on the basis of
567 the presence or absence of test bands. Three *L*. (*Viannia*) strains used as positive controls
568 were detected (i.e., showing a strong T-line and a very weak or missing C-line) by both
569 LAMP-CRISPR assays (Fig 4B, strips # 3-5). The negative controls (human gDNA and
570 NTC) had a negative test result (Fig 4B, strips # 1 and 2). There was no cross-reactivity

571 to other microbial pathogens tested (Fig 4B, strips # 6-10, which show a strong C-line
572 and a faint (or absent) T-line, similar to the negative controls).
573
574
575 **Fig 4. Analytical specificity testing of kDNA and 18S LAMP-CRISPR assays**. The
576 specificity of the kDNA and 18S LAMP-CRISPR assays was evaluated using gDNA from
577 reference strains of *Leishmania* spp. and other microbial pathogens (see Table 1 and S5
578 Fig). (A) Heat maps depicting LAMP-CRISPR fluorescence-based detection data from
579 tested reference strain samples. The color scale represents normalized fluorescence
580 signals from Cas12a reactions (i.e., fluorescence signals taken at t = 25 min in the test
581 sample relative to the NTC) for *Leishmania* kDNA and 18S rDNA targets. The
582 fluorescence ratio values from 2 independent assay repeats were entered into GraphPad;
583 the mean of these replicates is displayed. A fluorescence ratio ≥ 2 is considered detected.
584 (B) Cas12a reactions were performed using a biotin-FAM reporter molecule and
585 visualized on lateral flow strips. Uncleaved reporter molecules are captured at the first
586 detection line (control line), whereas collateral Cas12a cleavage activity generates a
587 signal at the second detection line (test line). The arrow indicates the direction of flow.
588 Top panel: kDNA LAMP-CRISPR assay; bottom panel: 18S LAMP-CRISPR assay.
589 Negative controls: HC, human control (gDNA from PBMCs of a healthy donor) (strip #
590 1); NC, no-template control (NTC) (strip # 2). Positive controls: Lbra, *L. braziliensis*
591 M2904 (strip # 3); Lguy, *L. guyanensis* M4147 (strip # 4); Lper, *L. peruviana* LCA08
592 (strip # 5). Non-related microbes: Mtb, *M. tuberculosis* PA155-18C (strip # 6); Pf, *P.*
593 *falciparum* HB3 (strip # 7). *T. cruzi* (Tc) strains: Tulahuen, Sylvio X10, and VT-1 (strips
594 # 8-10).
595

596

597 **Performance evaluation of LAMP-CRISPR assays with clinical samples**

598 Positive patient samples exhibited robust fluorescence curves in the Cas12a assay
599 indicating the presence of *Leishmania* kDNA (S6A Fig) or 18S rDNA (S6B Fig)
600 molecules. These results were consistent with the respective positive LAMP reactions as
601 visualized on an agarose gel (S6C and S6D Fig). We noted that the analysis of LAMP
602 products by agarose gel electrophoresis can sometimes give ambiguous (or difficult to
603 interpret) results. For instance, ladder-like bands were observed for samples S72 and S09
604 amplified by the 18S LAMP assay (S6D Fig), although the band pattern was different
605 from the one observed for true positive reactions. This was clearly resolved by the
606 Cas12a-based assay on those amplicons, which confirmed that S72 and S09 were negative
607 for *Leishmania* 18S rDNA molecules (S6B Fig).

608 We next evaluated the performance of our LAMP-CRISPR fluorescence-based
609 detection assays using gDNA from 90 clinical samples of skin lesions. An in-house qPCR
610 assay [64] targeting a kDNA minicircle region conserved among *Leishmania* (*Viannia*)
611 species [68] served as the reference test. Of the 90 samples, 55 were *Leishmania*-positive
612 and 35 were negative by qPCR.

613 To determine the cutoff value for discriminating between *Leishmania*-positive
614 and –negative samples by the LAMP-CRISPR assays, we used the mean of the
615 fluorescence ratio of negative samples + 3SD. To this end, an independent panel of
616 negative samples was used: n = 19 for the kDNA assay and n = 10 for the 18S assay (S1
617 Dataset). A higher number of negative samples was needed for the former to capture the
618 inter-assay variation in raw fluorescence signal from the Cas12a reaction that was evident
619 over different periods of sample testing (S1 Dataset). The determined cutoff value was
620 1.46 for the kDNA assay and 1.30 for the 18S assay (S1 Dataset).

621 The kDNA LAMP-CRISPR assay detected 50 (90.9%) of 55 qPCR-positive
622 samples (Fig 5 and 6A, Table 2, and S1 Dataset). Of these, the 5 samples not detected by
623 kDNA LAMP-CRISPR (coded 3, 5, 6, 28 and 71) harbored low parasite loads (≤20
624 parasites/10^6 human cells) (Fig 6B and S1 Dataset), corresponding to 10^{-2} to 10^{-3} parasite
625 GE/reaction (S1 Dataset, see "Parasite equivalents" data in the worksheet "qPCR_CS").
626 The 18S LAMP-CRISPR assay detected 40 (72.7%) of 55 qPCR-positive samples (Fig 5
627 and 6C, Table 2, and S1 Dataset). Of these, the 15 samples not detected by 18S LAMP-
628 CRISPR contained a parasite load of ≤150 parasites/10^6 human cells (Fig 6D and S1
629 Dataset), which corresponded to 10^{-1} to 10^{-3} parasite GE/reaction (S1 Dataset, see
630 "Parasite equivalents" data in the worksheet "qPCR_CS"). Both LAMP-CRISPR assays
631 achieved 100% specificity (Table 2). The complete dataset of this study is presented in
632 the S1 Dataset.

633 A ROC curve analysis was used to assess the performance of each assay in
634 distinguishing *Leishmania*-positive and -negative clinical samples, with AUC values of
635 0.973 for the kDNA LAMP-CRISPR assay (Fig 7A) and 0.876 for the 18S LAMP-
636 CRISPR assay (Fig 7B).

637

638

639 **Fig 5. Evaluation of kDNA and 18S LAMP-CRISPR assay performance on clinical**
640 **samples**. Heat maps showing LAMP-CRISPR fluorescence-based detection data from
641 tested clinical samples (n = 90). The color scale represents normalized fluorescence
642 signals from Cas12a reactions (i.e., fluorescence signals taken at t = 25 min in the test
643 sample relative to the NTC) for *Leishmania* kDNA and 18S rDNA targets. Samples are
644 coded as 1-90 ('Code_UPC' as indicated in the S1 Dataset). PC, positive control (*L.*
645 *braziliensis* M2904 gDNA, 10^3 – 10^4 genome equivalents); NC, no-template control

646 (NTC) of the LAMP reaction. The cutoff value was 1.46 for the kDNA assay and 1.30
647 for the 18S assay (mean of the fluorescence ratio of negative clinical samples used to
648 calculate cutoff values + 3SD; see the S1 Dataset). The Cq values corresponding to the
649 kDNA qPCR assay (reference test) are shown. For Cq values, the letter "U" denotes
650 undetermined; X, not applicable.
651
652
653 **Fig 6. Evaluation of kDNA and 18S LAMP-CRISPR assay performance on clinical**
654 **samples: analysis across the range of parasite load levels**. (A, C) Scatter plots showing
655 normalized fluorescence signals from Cas12a reactions (i.e., fluorescence signals taken
656 at t = 25 min in the test sample relative to the NTC) for *Leishmania* kDNA (A) and 18S
657 rDNA (C) targets in clinical samples (n = 90; data shown in Fig 5 and S1 Dataset) versus
658 Cq values determined by kDNA qPCR. (B, D) Scatter plots showing normalized
659 fluorescence signals from Cas12a reactions for *Leishmania* kDNA (B) and 18S rDNA
660 (D) targets in clinical samples versus the estimated parasite load in quantifiable samples
661 (n = 55). The parasite load is expressed as the number of *Leishmania* parasites/10^6 human
662 cells. The horizontal dotted lines represent the LAMP-CRISPR assay cutoff value (mean
663 of the fluorescence ratio of negative clinical samples + 3SD; see the S1 Dataset): 1.46 for
664 the kDNA assay and 1.30 for the 18S assay.
665
666
667
668
669

670 **Table 2. Diagnostic performance of LAMP-CRISPR assays with fluorescence**

671 **readout for *Leishmania* DNA detection compared with the kDNA qPCR assay**

	kDNA qPCR		% (95% CI)	
Test	Positive (n = 55)	Negative (n = 35)	Sensitivity	Specificity
kDNA LAMP-CRISPR			90.91 (80.05-96.98)	100.00 (90.00-100.00)
Positive	50	0		
Negative	5	35		
18S LAMP-CRISPR			72.73 (59.04-83.86)	100.00 (90.00-100.00)
Positive	40	0		
Negative	15	35		

672 Results of the statistical analysis of diagnostic test performance conducted with the MedCalc software

673 version 23.0.1. (https://www.medcalc.org/calc/diagnostic_test.php)

674

675

676 **Fig 7. Evaluation of kDNA and 18S LAMP-CRISPR assay performance on clinical**

677 **samples: ROC curve analysis**. ROC curve analysis performed using the fluorescence

678 ratio values of the kDNA LAMP-CRISPR assay (A) or the 18S LAMP-CRISPR assay

679 (B) from tested clinical samples (n = 90; data shown in Fig 5 and S1 Dataset), with the

680 *Leishmania* infection status (positive/negative) as determined by kDNA qPCR (reference

681 test). The area under the curve (AUC) and corresponding 95% confidence interval

682 (calculated using the Wilson/Brown method) are shown. The diagonal dotted line

683 corresponds to the null hypothesis with AUC of 0.5, in which the accuracy of a diagnostic

684 test is no different from random chance.

685

686

687 We also assessed the applicability of the LAMP-CRISPR assays with an LFA
688 readout on clinical samples. To this end, we performed pilot testing on gDNA extracted
689 from a representative group of clinical samples (n = 18) encompassing a wide range of
690 parasite load levels as determined by the kDNA qPCR assay. Lateral flow testing results
691 were consistent across two assay repeats per sample (n = 8; S7 Fig), indicating robust
692 assay reproducibility. Subsequently, we expanded the evaluation to include 10 additional
693 clinical samples, thus analyzing a total of 18 specimens (Fig 8). Samples that tested
694 positive by the kDNA LAMP-CRISPR assay (16/18 = 88.9%) included the 3 parasite load
695 categories: low (4 of 6 tested), intermediate (6 of 6), and high (6 of 6) (Fig 8). These LFA
696 results were 100% concordant with the fluorescence-based readout (Fig 8 and S1
697 Dataset). The 18S LAMP-CRISPR assay with LFA readout detected *Leishmania* DNA in
698 72.2% (13/18) of the examined samples, which had parasite load levels defined as: low
699 (2 of 6 tested), intermediate (5 of 6), and high (6 of 6) (Fig 8). One sample (coded 12) out
700 of the 18 tested samples (5.6%) by the 18S assay showed discordant results between LFA
701 and fluorescence-based readouts (Fig 8), with this associated with a low parasite load
702 (56.6 parasites/10^6 human cells) (S1 Dataset). The two examined DNA samples from non-
703 leishmaniasis patients (i.e., kDNA qPCR-negative; samples 09 and C7) tested negative
704 by both LAMP-CRISPR assays (Fig 8 and S7 Fig).
705
706
707 **Fig 8. Pilot testing of kDNA and 18S LAMP-CRISPR assays on clinical samples**
708 **using a lateral flow readout**. A representative subset of clinical samples with varying
709 parasite load levels was tested with kDNA and 18S LAMP-CRISPR assays using a LFA
710 readout. Visualization on the lateral flow strips (Milenia GenLine HybriDetect strips) was
711 achieved through the cleavage of the biotin-FAM reporter molecule. C, control line; T,

712 test line. The results of the fluorescence-based readout of the LAMP-CRISPR assays (+,
713 detected; -, not detected, on the basis of the estimated cutoff; see S1 Dataset) as well as
714 the Cq values of the kDNA qPCR are indicated below each strip. Controls included DNA
715 samples from two non-leishmaniasis patients (i.e., kDNA qPCR-negative; samples 09 and
716 C7), a positive control (PC, 2×10^2 genome equivalents from *L. braziliensis* M2904
717 gDNA), a human negative control (HC, 20 ng of human PBMC gDNA), and a no-
718 template control (NTC) of the LAMP reaction.
719

720 ## Discussion

721 The pressing need for new diagnostic tools has been identified as a priority in the World
722 Health Organization (WHO) 2030 road map to support the control and elimination of
723 neglected tropical diseases [69]. Among them, leishmaniasis belongs to the category of
724 the most neglected ones as it entails a group of diseases with a large negative impact on
725 people living in endemic rural areas, who are often economically disadvantaged and do
726 not have access to an early, correct disease diagnosis that would enable timely adequate
727 treatment. PCR-based molecular diagnostics provide the most sensitive and specific tools
728 for *Leishmania* detection and are pivotal for early disease diagnosis, discrimination of
729 *Leishmania* species, detection of asymptomatic infections, and epidemiological
730 surveillance [70]. Besides their use in centralized laboratories, the progress in the
731 automation and simplification of the workflow from sample preparation to target
732 amplification and detection (result readout) steps has made molecular diagnostics more
733 suitable and accessible for resource-limited settings in the form of near-PoC tests [71].
734 Examples of promising formats include the *Leishmania* OligoC-TesT (a PCR-
735 oligochromatographic test) [72, 73] and a PCR-based method applied directly on EDTA
736 blood for the diagnosis of VL, where the PCR is run on a portable miniPCR device and

737 the labeled PCR products are detected with a lateral flow immunoassay [74]. Other recent
738 advances have been facilitated by the incorporation of isothermal NAATs, such as LAMP
739 and RPA, combined with lateral flow detection or other portable devices [75-79]. Among
740 the most promising approaches is the integration of isothermal NAATs with CRISPR
741 technology, which has fostered the development of a new generation of molecular
742 diagnostics with the potential to advance toward near-PoC applications in low-resource
743 settings [80].

744 In the present study, we aimed to contribute with the development of LAMP-
745 coupled CRISPR-Cas12a assays for molecular detection of *Leishmania* spp. We designed
746 new LAMP primer sets that flank previously reported crRNA target sites [45] within two
747 commonly used multicopy regions of the *Leishmania* genome: the 18S rDNA and kDNA
748 minicircles. We harnessed the CRISPR-Cas12a system as the detection method to avoid
749 possible false positive results caused by non-specific amplification in the LAMP reaction
750 and thereby improve the assay's specificity. The assay process can be completed within
751 1.5 h, with results readable via either of the two optimized readouts: a fluorescence-based
752 readout (suitable for laboratories with minimal molecular biology equipment such as a
753 blue light transilluminator or a handheld fluorimeter) and a visual readout on lateral flow
754 strips (to simplify the use of these assays). We report on the analytical validation and
755 initial performance evaluation of our assays in clinical samples under controlled
756 conditions in a research laboratory setting. With these achievements, compared to our
757 previous proof-of-concept PCR-CRISPR assays [45], we aim to pave the way towards
758 making CRISPR-based diagnostics accessible in a testing kit format for the diagnosis of
759 leishmaniasis in rural endemic areas.

760 Here, in keeping with our *in silico* primer and crRNA design within conserved
761 target genomic regions, the analytical validation demonstrated the ability of the 18S

762 LAMP-CRISPR assay to achieve pan-*Leishmania* detection, whereas the kDNA LAMP-
763 CRISPR assay reliably detected species belonging to the *Leishmania* (*Viannia*) subgenus.
764 The kDNA assay also detected certain strains from the analyzed species of the *L.*
765 (*Leishmania*) subgenus, specifically *L. mexicana* from Central America and *L. donovani*
766 from the Old World. These results reflect both the similarity and variations in
767 mitochondrial kDNA minicircle sequences between the two subgenera (see S1 Fig).
768 Furthermore, our assays showed no cross-reactivity against other pathogens tested, which
769 co-circulate in the same geographic regions and can thus coinfect the same human host,
770 such as *T. cruzi* (a closely related trypanosomatid), *P. falciparum*, and *M. tuberculosis*,
771 or cause cutaneous lesions similar to CL (*M. tuberculosis*) [81]. Our LAMP-CRISPR
772 assays achieved high analytical sensitivity on serially diluted DNA from the *L.*
773 *braziliensis* M2904 strain, with a detection level equivalent to 0.2 parasites per reaction.
774 This detection sensitivity (below one parasite genome equivalent) compares well with
775 that of the reference kDNA qPCR assay (5×10^{-3} genome equivalents per reaction; [64]),
776 which is clinically relevant.

777 To explore the performance of our LAMP-CRISPR assays to detect *Leishmania*
778 DNA in clinical samples, we evaluated a blinded panel of human skin lesion samples (n=
779 90) from patients enrolled in the Cusco region of Peru, where CL is caused by *L.* (*Viannia*)
780 species. Both LAMP-CRISPR assays with a fluorescence readout attained good
781 diagnostic performance, with sensitivity rates of 90.9% for kDNA and 72.7% for 18S
782 rDNA, and a specificity of 100%, compared to the reference kDNA qPCR assay.
783 Discrepancies between the two methods corresponded to samples with low parasite loads
784 (S1 Dataset). Overall, LAMP-CRISPR assay results for the subgroup of samples tested
785 with both fluorescence-based and lateral flow strip readouts were concordant. The 18S
786 LAMP-CRISPR assay showed a somewhat reduced sensitivity when applied to clinical

787 samples. This is likely related to the differences in target copy number: *Leishmania*
788 parasites present an estimated 10 to 170 copies of the nuclear 18S rDNA region per
789 genome [82, 83], while they harbor about 10,000 copies of extrachromosomal kDNA
790 minicircles per cell [84].

791 Several studies have developed prototype LAMP assays for detecting *Leishmania*
792 infections in diagnosing human VL, CL, and post-kala-azar dermal leishmaniasis
793 (PKDL), as well as in domestic animal reservoirs (dogs) and sand flies. They target
794 multicopy genomic regions, such as kDNA minicircles [85-87], the 18S rRNA gene [88-
795 90], the ITS1 region in the rDNA array [91], and cysteine proteinase B (*cpb*) genes [92].
796 These assays proved to be highly sensitive for the detection of VL- and CL-causing
797 *Leishmania* species (at the genus, species complex, or species level, depending on the
798 target used), underscoring their potential value as diagnostic and surveillance tools in
799 endemic settings. With the genus-specific targets, because of their high sequence
800 conservation among the Trypanosomatidae, some nonspecific results were observed. For
801 instance, the study of Adams *et al*. [88] reported on a LAMP assay based on 18S rDNA
802 that was unable to discriminate between infections with *Leishmania*, *T. brucei*, and *T.*
803 *cruzi*. Since the diseases caused by these related pathogens differ in clinical presentation,
804 their differential diagnosis can be made on clinical symptoms and confirmed using a
805 species-specific LAMP assay designed for this purpose [88]. In this study, when we tested
806 our 18S LAMP primer set - crRNA combination, no cross-reactivity was observed with
807 DNA from 3 *T. cruzi* strains belonging to different genetic lineages known as discrete
808 typing units (DTUs), namely DTU TcI (Sylvio X10 strain), DTU TcIV (VT-1 strain), and
809 DTU TcVI (Tulahuen LacZ clone C4 strain). Our results demonstrate the high analytical
810 specificity of the LAMP-CRISPR assay towards *Leishmania* spp. We also noted that
811 integrating LAMP amplification with downstream CRISPR-based detection improved

812 discrimination between positive and negative amplification results, as shown in previous
813 studies [37, 56]. This outcome is due to the LAMP-coupled CRISPR assays offering two
814 layers of specificity: the first one enabled by using 4 to 6 LAMP primers that selectively
815 target 6 to 8 distinct regions in the target DNA, and the second one due to the crRNA-
816 guided Cas12a-mediated target sequence recognition [23]. An optimization to improve
817 the LAMP assay specificity involves incorporating a probe-specific detection readout
818 [18], as illustrated in the study by Ruang-Areerate *et al*. [93] aimed at detecting
819 asymptomatic *Leishmania* infections in HIV-infected patients.

820 The LAMP technology is commercially available and delivered, such as the
821 *Leishmania* detection kit (Loopamp™ *Leishmania* Detection Kit; Eiken Chemical Co.,
822 Ltd., Japan), which does not require cold-chain storage. This kit targets kDNA minicircles
823 and 18S rDNA in the same reaction to enable pan-*Leishmania* detection based on the
824 LAMP assay developed by Adams *et al*. [94]. The diagnostic performance evaluation of
825 this kit in different endemic areas around the world has demonstrated its high sensitivity
826 and specificity for the diagnosis of VL [22, 76, 94-96], CL [22, 94, 97, 98], and PKDL
827 [99], underscoring its potential for implementation in primary healthcare facilities.
828 Undoubtedly, the DNA extraction method can impact LAMP assay performance when
829 testing clinical samples. As shown in the study by Ghosh *et al*. [99], a lower efficiency of
830 LAMP to diagnose PKDL was observed when the LAMP reaction was performed using
831 crude DNA obtained by a simple in-house boil and spin protocol compared to DNA
832 extracted by a commercial silica column-based (Qiagen) kit (67.2% vs. 89.7% sensitivity,
833 respectively). Further, a recent study found a compromised sensitivity (48.4%) of the
834 *Leishmania* LAMP kit for the diagnosis of CL in Ethiopia, possibly due to a primer
835 mismatch with the *L. aethiopica* 18S rDNA target [100]. This finding points out the need
836 to extensively validate existing LAMP assays in diverse clinical contexts and

837 epidemiological scenarios in different geographical areas to confirm their effectiveness
838 in detecting local parasite variants that are circulating. The same applies to our new
839 LAMP-CRISPR assays.

840 Combining highly sensitive isothermal amplification with the notable highly
841 specific CRISPR-Cas12a system is an approach that has been applied for detecting
842 pathogenic trypanosomatids. For example, Wiggins *et al*. [46] developed proof-of-
843 concept RPA-coupled CRISPR-Cas12a assays that target kDNA maxicircles for
844 *Leishmania* spp. detection. They have recently adapted their assays into a
845 multichambered device to obtain a rapid nucleic acid diagnostic tool that does not require
846 electricity or instrumentation, a promising development for diagnostic applications in
847 low-resource settings [101]. In another study, Yang *et al*. [47] developed a one-tube RPA-
848 CRISPR/Cas12a assay that targets the *Leishmania Kmp11* gene. The assay process can
849 be completed within 50 min, with the fluorescent signal of reaction tubes observed
850 visually under blue light illumination. Their assay has been evaluated on simulated
851 clinical samples, yielding a sensitivity of 97.9% and a specificity of 100%. Ortiz-
852 Rodríguez *et al*. [50] developed a platform for *T. cruzi* detection, which was validated on
853 samples from reservoirs and insect vectors. It employs PCR or RPA followed by
854 CRISPR-Cas12a-based detection. Of 3 nuclear target genes evaluated, namely
855 cytochrome B (*Cytb*), the 18S rRNA gene, and histone H2A, only the former (*Cytb*)
856 resulted in a workable CRISPR-based assay since no mutations were found in the chosen
857 target site during testing of *T. cruzi* DNA extracted from the intestine of triatomine
858 vectors. Furthermore, the authors designed a portable prototype device (called TropD-
859 Detector) for fluorescence results discrimination, suitable for low-resource settings.
860 Guarnizo *et al*. [56] designed a LAMP-CRISPR/Cas12a assay that targets a highly
861 conserved region in the nuclear *HSP70* gene to specifically detect *T. cruzi* in the context

862 of acute Chagas disease diagnosis in endemic countries. They evaluated the assay in
863 clinical samples from 100 infants born to Chagas-positive mothers in Bolivia, achieving
864 a sensitivity of 77.27% and a specificity of 100% compared to a TaqMan-based qPCR
865 assay that targets satellite DNA.

866 Our study shows that LAMP-coupled CRISPR-Cas12a assays are an effective
867 alternative method for detecting *Leishmania* infections in different non-invasive and
868 invasive specimens (S1 Dataset) from human skin lesions. While kDNA LAMP primers
869 previously reported were for a *L. donovani* complex-specific assay [94] or for a *L.*
870 *amazonensis*-specific assay [87], our kDNA LAMP-CRISPR assay (specifically the
871 crRNA design) exploited a kDNA minicircle region conserved in the New World species
872 of the *Leishmania* (*Viannia*) subgenus ([45] and S1 Fig). Our pan-*Leishmania* 18S
873 LAMP-CRISPR assay is expected to be capable of detecting various parasite species from
874 both the New and Old World (S2 Fig). Our findings encourage further evaluation and
875 validation of both assays in different geographical areas. Besides, our assays have the
876 potential to be adapted in future work to address the ASSURED/REASSURED criteria
877 for a diagnostic test suitable for adoption across different healthcare levels, which require
878 assays to be affordable, sensitive, specific, user-friendly, robust and rapid, as well as
879 equipment-free (or operating with minimal equipment), deliverable to those who need
880 them, with real-time connectivity, and workable on easily collected specimens [102, 103].
881 Sample preparation is one of the challenges in molecular assay implementation in
882 resource-limited settings [104]. Further research is needed to optimize rapid DNA
883 extraction protocols, such as boil-spin [99] and SpeedXtract (a magnetic bead-based
884 method) [105], combined with a streamlined CRISPR assay workflow to move forward
885 to a near-PoC nucleic acid-based diagnostic assay for CL and other forms of
886 leishmaniasis. Both LAMP and CRISPR reactions are compatible with freeze-drying

887 (lyophilization), which improves reagent stability for easy transport and storage at room
888 temperature and may reduce contamination risks [106]. This improvement can also
889 facilitate the preparation of the assays in a pre-designed kit format, enabling a portable
890 assay setup for resource-limited settings. Therefore, the impact of freeze-drying reagents
891 on the performance of our assays needs to be evaluated in future work. Incorporating
892 these refinements into our assay procedure, along with user-friendly devices, such as the
893 LFA strips or a handheld fluorimeter, would allow its adoption in minimally-equipped
894 laboratories in endemic regions, and may be incorporated in a mobile suitcase laboratory.
895 The latter approach has been explored with a RPA assay in field studies conducted in
896 Asia, showing promising performance for VL, PKDL, and CL diagnosis in endemic
897 settings [105, 107, 108]. After further optimization and validation, we envisage that our
898 LAMP-CRISPR assays may become valuable tools for providing rapid testing results
899 directly in the affected regions, thereby mitigating delays associated with testing in
900 centralized laboratories. CRISPR-based assays could also have a considerable role in
901 epidemiological studies, in providing real-time surveillance data. Further, an approach
902 for future work that offers the potential to be impactful in resource-limited endemic
903 settings entails the integration of our assays with recent developments in lab-on-chip
904 systems, such as a paper-based LAMP-CRISPR integrated diagnostic platform (PLACID)
905 [37]. This paper-based device uses freeze-dried LAMP and CRISPR reagents, where
906 nucleic acid amplification and CRISPR reactions are performed successively without
907 fluid transfer using paper microfluidics. A smartphone-based protocol allows the
908 fluorescent detection of nucleic acid targets. This platform showed robust performance
909 for bacterial and viral pathogen target detection, with no false positives observed [37].
910 These are well-known refinements to consider in future assay development efforts.
911 Indeed, we noticed that our current two-step LAMP-CRISPR open assay format

intrinsically carries the risk of cross-contamination during sample transfer from tube-based (LAMP) to plate-based (CRISPR) reactions, as reported in other studies [106].

In conclusion, we developed novel LAMP-CRISPR assays for the molecular detection of *Leishmania*, targeting two multicopy genomic regions: 18S rDNA for pan-*Leishmania* detection and a kDNA minicircle region conserved among New World *L.* (*Viannia*) species. By integrating LAMP with CRISPR-Cas12a technology, the assays enable accurate detection, with results readout via fluorescence or lateral flow strips, the latter aimed at facilitating a simpler workflow. Analytical validation and initial performance testing on clinical samples demonstrated high sensitivity and specificity, underscoring the assays' potential as effective alternatives for detecting *Leishmania* infections. With further optimization and validation, these prototype assays hold promise as next-generation molecular tools with great potential to improve the diagnosis and surveillance of leishmaniasis in endemic regions, thereby supporting One Health strategies for disease control.

References

1. World Health Organization. Leishmaniasis. World Health Organization: WHO. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
2. Pan American Health Organization. Leishmaniasis. Pan American Health Organization: PAHO. 2017. Available from: https://www3.paho.org/hq/dmdocuments/2017/2017-cha-leishmaniasis-factsheet-work.pdf
3. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671.

4. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018 Sep 15;392(10151):951-970.
5. Pan American Health Organization. Leishmaniasis: Epidemiological Report for the Americas. No.12. 2023 Dec 21. Available from: https://iris.paho.org/handle/10665.2/59155
6. Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol. 2016 Sep;16(9):581-92.
7. Kaye PM, Cruz I, Picado A, Van Bocxlaer K, Croft SL. Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs. Semin Immunopathol. 2020 Jun;42(3):247-264.
8. Reimão JQ, Coser EM, Lee MR, Coelho AC. Laboratory Diagnosis of Cutaneous and Visceral Leishmaniasis: Current and Future Methods. Microorganisms. 2020 Oct 22;8(11):1632.
9. Van der Auwera G, Dujardin JC. Species typing in dermal leishmaniasis. Clin Microbiol Rev. 2015 Apr;28(2):265-94.
10. Akhoundi M, Downing T, Votýpka J, Kuhls K, Lukeš J, Cannet A, et al. *Leishmania* infections: Molecular targets and diagnosis. Mol Aspects Med. 2017 Oct;57:1-29.
11. Mesa LE, Manrique R, Muskus C, Robledo SM. Test accuracy of polymerase chain reaction methods against conventional diagnostic techniques for Cutaneous Leishmaniasis (CL) in patients with clinical or epidemiological suspicion of CL: Systematic review and meta-analysis. PLoS Negl Trop Dis. 2020 Jan 21;14(1):e0007981.

12. Bharadwaj M, Bengtson M, Golverdingen M, Waling L, Dekker C. Diagnosing point-of-care diagnostics for neglected tropical diseases. PLoS Negl Trop Dis. 2021 Jun 17;15(6):e0009405.
13. Oliveira BB, Veigas B, Baptista PV. Isothermal Amplification of Nucleic Acids: The Race for the Next "Gold Standard." Front. Sens. 2021 Sep 28;2:752600.
14. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000 Jun 15;28(12):E63.
15. Nagamine K, Watanabe K, Ohtsuka K, Hase T, Notomi T. Loop-mediated isothermal amplification reaction using a nondenatured template. Clin Chem. 2001 Sep;47(9):1742-3.
16. Mori Y, Nagamine K, Tomita N, Notomi T. Detection of loop-mediated isothermal amplification reaction by turbidity derived from magnesium pyrophosphate formation. Biochem Biophys Res Commun. 2001 Nov 23;289(1):150-4.
17. Mori Y, Hirano T, Notomi T. Sequence specific visual detection of LAMP reactions by addition of cationic polymers. BMC Biotechnol. 2006 Jan 10;6:3.
18. Phillips EA, Moehling TJ, Bhadra S, Ellington AD, Linnes JC. Strand Displacement Probes Combined with Isothermal Nucleic Acid Amplification for Instrument-Free Detection from Complex Samples. Anal Chem. 2018 Jun 5;90(11):6580-6586.
19. Atçeken N, Yigci D, Ozdalgic B, Tasoglu S. CRISPR-Cas-Integrated LAMP. Biosensors (Basel). 2022 Nov 17;12(11):1035. doi: 10.3390/bios12111035.

983 20. Nzelu CO, Kato H, Peters NC. Loop-mediated isothermal amplification (LAMP):
984 An advanced molecular point-of-care technique for the detection of *Leishmania*
985 infection. PLoS Negl Trop Dis. 2019 Nov 7;13(11):e0007698.
986 21. Erber AC, Sandler PJ, de Avelar DM, Swoboda I, Cota G, Walochnik J. Diagnosis
987 of visceral and cutaneous leishmaniasis using loop-mediated isothermal
988 amplification (LAMP) protocols: a systematic review and meta-analysis. Parasit
989 Vectors. 2022 Jan 24;15(1):34.
990 22. Ibarra-Meneses AV, Chicharro C, Sánchez C, García E, Ortega S, Ndung'u JM,
991 et al. Loop-Mediated Isothermal Amplification Allows Rapid, Simple and
992 Accurate Molecular Diagnosis of Human Cutaneous and Visceral Leishmaniasis
993 Caused by *Leishmania infantum* When Compared to PCR. Microorganisms. 2021
994 Mar 16;9(3):610.
995 23. Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-
996 based diagnostics. Nat Biomed Eng. 2021 Jul;5(7):643-656.
997 24. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-
998 Cas12a target binding unleashes indiscriminate single-stranded DNase activity.
999 Science. 2018 Apr 27;360(6387):436-439.
1000 25. Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al.
1001 Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017 Apr
1002 28;356(6336):438-442.
1003 26. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-
1004 Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020 Jul;38(7):870-874.
1005 27. Wang X, Ji P, Fan H, Dang L, Wan W, Liu S, et al. CRISPR/Cas12a technology
1006 combined with immunochromatographic strips for portable detection of African
1007 swine fever virus. Commun Biol. 2020 Feb 11;3(1):62.

1008 28. Li SY, Cheng QX, Wang JM, Li XY, Zhang ZL, Gao S, et al. CRISPR-Cas12a-
1009 assisted nucleic acid detection. Cell Discov. 2018 Apr 24;4:20.
1010 29. Cunningham CH, Hennelly CM, Lin JT, Ubalee R, Boyce RM, Mulogo EM, et
1011 al. A novel CRISPR-based malaria diagnostic capable of *Plasmodium* detection,
1012 species differentiation, and drug-resistance genotyping. EBioMedicine. 2021
1013 Jun;68:103415.
1014 30. Nguyen LT, Smith BM, Jain PK. Enhancement of trans-cleavage activity of
1015 Cas12a with engineered crRNA enables amplified nucleic acid detection. Nat
1016 Commun. 2020 Sep 30;11(1):4906.
1017 31. Fozouni P, Son S, Díaz de León Derby M, Knott GJ, Gray CN, D'Ambrosio MV,
1018 et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and
1019 mobile phone microscopy. Cell. 2021 Jan 21;184(2):323-333.e9.
1020 32. Liu TY, Knott GJ, Smock DCJ, Desmarais JJ, Son S, Bhuiya A, et al. Accelerated
1021 RNA detection using tandem CRISPR nucleases. Nat Chem Biol. 2021
1022 Sep;17(9):982-988.
1023 33. Nalefski EA, Patel N, Leung PJY, Islam Z, Kooistra RM, Parikh I, et al. Kinetic
1024 analysis of Cas12a and Cas13a RNA-Guided nucleases for development of
1025 improved CRISPR-Based diagnostics. iScience. 2021 Aug 18;24(9):102996.
1026 34. Wang DG, Brewster JD, Paul M, Tomasula PM. Two methods for increased
1027 specificity and sensitivity in loop-mediated isothermal amplification. Molecules.
1028 2015 Apr 7;20(4):6048-59.
1029 35. Joung J, Ladha A, Saito M, Kim NG, Woolley AE, Segel M, et al. Detection of
1030 SARS-CoV-2 with SHERLOCK One-Pot Testing. N Engl J Med. 2020 Oct
1031 8;383(15):1492-1494.

1032 36. Wang R, Qian C, Pang Y, Li M, Yang Y, Ma H, et al. opvCRISPR: One-pot visual
1033 RT-LAMP-CRISPR platform for SARS-cov-2 detection. Biosens Bioelectron.
1034 2021 Jan 15;172:112766.
1035 37. Sen A, Masetty M, Weerakoon S, Morris C, Yadav JS, Apewokin S, et al. Paper-
1036 based loop-mediated isothermal amplification and CRISPR integrated platform
1037 for on-site nucleic acid testing of pathogens. Biosens Bioelectron. 2024 Aug
1038 1;257:116292.
1039 38. Mukama O, Yuan T, He Z, Li Z, Habimana J de D, Hussain M, et al. A high
1040 fidelity CRISPR/Cas12a based lateral flow biosensor for the detection of HPV16
1041 and HPV18. Sensors and Actuators B: Chemical. 2020 Aug;316:128119. pii:
1042 S092540052030469X. doi: 10.1016/j.snb.2020.128119.
1043 39. Wang Y, Li J, Li S, Zhu X, Wang X, Huang J, et al. LAMP-CRISPR-Cas12-based
1044 diagnostic platform for detection of *Mycobacterium tuberculosis* complex using
1045 real-time fluorescence or lateral flow test. Mikrochim Acta. 2021 Sep
1046 20;188(10):347.
1047 40. Qiu X, Liu X, Ma X, Wang R, Chen S, Li F, et al. One-Pot Isothermal LAMP-
1048 CRISPR-Based Assay for *Klebsiella pneumoniae* Detection. Microbiol Spectr.
1049 2022 Aug 31;10(4):e0154522.
1050 41. Fang Y, Liu L, Zhao W, Dong L, He L, Liu Y, et al. Rapid and Sensitive Detection
1051 of *Verticillium dahliae* from Soil Using LAMP-CRISPR/Cas12a Technology. Int
1052 J Mol Sci. 2024 May 10;25(10):5185.
1053 42. Lee RA, Puig H, Nguyen PQ, Angenent-Mari NM, Donghia NM, McGee JP, et
1054 al. Ultrasensitive CRISPR-based diagnostic for field-applicable detection
1055 of *Plasmodium* species in symptomatic and asymptomatic malaria. Proc Natl
1056 Acad Sci U S A. 2020 Oct 13;117(41):25722-25731.

1057 43. Wang X, Cheng M, Yang S, Xing C, Li Q, Zhu Y, et al. CRISPR/Cas12a
1058 combined with RPA for detection of *T. gondii* in mouse whole blood. Parasit
1059 Vectors. 2023 Jul 30;16(1):256.
1060 44. Bengtson M, Bharadwaj M, Franch O, van der Torre J, Meerdink V, Schallig H,
1061 et al. CRISPR-dCas9 based DNA detection scheme for diagnostics in resource-
1062 limited settings. Nanoscale. 2022 Feb 3;14(5):1885-1895.
1063 45. Dueñas E, Nakamoto JA, Cabrera-Sosa L, Huaihua P, Cruz M, Arévalo J, et al.
1064 Novel CRISPR-based detection of *Leishmania* species. Front Microbiol. 2022 Sep
1065 15;13:958693.
1066 46. Wiggins TJ, Peng R, Bushnell RV, Tobin JK, MacLeod DA, Du K, et al.
1067 Instrument-Free Point-of-Care Diagnostic for *Leishmania* Parasites. Diagnostics
1068 (Basel). 2024 Dec 5;14(23):2744.
1069 47. Yang K, Bi M, Mo X. CRISPR/Cas12a, combined with recombinase polymerase
1070 amplification (RPA) reaction for visual detection of *Leishmania* species.
1071 Microchem J. 2024 Dec;207:112283. doi: 10.1016/j.microc.2024.112283
1072 48. Sima N, Dujeancourt-Henry A, Perlaza BL, Ungeheuer MN, Rotureau B, Glover
1073 L. SHERLOCK4HAT: A CRISPR-based tool kit for diagnosis of Human African
1074 Trypanosomiasis. EBioMedicine. 2022 Nov;85:104308.
1075 49. Álvarez-Rodríguez A, Li Z, Jin BK, Stijlemans B, Geldhof P, Magez S. A
1076 CRISPR-Cas-based recombinase polymerase amplification assay for ultra-
1077 sensitive detection of active *Trypanosoma brucei evansi* infections. Front Mol
1078 Biosci. 2025 Feb 14;12:1512970.
1079 50. Ortiz-Rodríguez LA, Cabanzo R, Jaimes-Dueñez J, Mendez-Sanchez SC, Duque
1080 JE. TropD-detector a CRISPR/LbCas12a-based system for rapid screening of

1081 *Trypanosoma cruzi* in Chagas vectors and reservoirs. Sci Rep. 2025 May
1082 31;15(1):19107.
1083 51. Cherkaoui D, Mesquita SG, Huang D, Lugli EB, Webster BL, McKendry RA.
1084 CRISPR-assisted test for *Schistosoma haematobium*. Sci Rep. 2023 Mar
1085 27;13(1):4990.
1086 52. MacGregor SR, McManus DP, Sivakumaran H, Egwang TG, Adriko M, Cai P, et
1087 al. Development of CRISPR/Cas13a-based assays for the diagnosis of
1088 Schistosomiasis. EBioMedicine. 2023 Aug;94:104730.
1089 53. Liu J, Wang X, Sheng F, Giri BR, Li S, Xia T, et al. Metagenomic sequencing for
1090 identifying pathogen-specific circulating DNAs and development of diagnostic
1091 methods for schistosomiasis. iScience. 2023 Jul 27;26(9):107495.
1092 54. Parikesit AA, Hermantara R, Gregorius K, Siddharta E. Designing hybrid
1093 CRISPR-Cas12 and LAMP detection systems for treatment-resistant *Plasmodium*
1094 *falciparum* with in silico method. Narra J. 2023 Dec;3(3):e301.
1095 55. Liang Y, Xie SC, Lv YH, He YH, Zheng XN, Cong W, et al. A novel single-tube
1096 LAMP-CRISPR/Cas12b method for rapid and visual detection of zoonotic
1097 *Toxoplasma gondii* in the environment. Infect Dis Poverty. 2024 Dec 10;13(1):94.
1098 56. Guarnizo SAG, Basma L, Equilia S, Condori BJ, Malaga E, Defazio S, et al. A
1099 specific, stable, and accessible LAMP assay targeting the HSP70 gene
1100 of *Trypanosoma cruzi*. medRxiv [Preprint]. 2025 Jan 13:2025.01.12.25320185.
1101 doi: 10.1101/2025.01.12.25320185.
1102 57. Kato H, Cáceres AG, Seki C, Silupu García CR, Holguín Mauricci C, Castro
1103 Martínez SC, et al. Further insight into the geographic distribution of *Leishmania*
1104 species in Peru by cytochrome b and mannose phosphate isomerase gene analyses.
1105 PLoS Negl Trop Dis. 2019 Jun 20;13(6):e0007496.

1106 58. Sandoval-Juárez A, Minaya-Gómez G, Rojas-Palomino N, Cáceres O.
1107 Identification of *Leishmania* species in patients derived to the National Institute
1108 of Health, Peru. Rev Peru Med Exp Salud Publica. 2020 Jan-Mar;37(1):87-92.
1109 59. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version
1110 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics.
1111 2009 May 1;25(9):1189-91.
1112 60. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable
1113 generation of high-quality protein multiple sequence alignments using Clustal
1114 Omega. Mol Syst Biol. 2011 Oct 11;7:539.
1115 61. Alcántara R, Peñaranda K, Mendoza-Rojas G, Nakamoto JA, Martins-Luna J, Del
1116 Valle-Mendoza J, et al. Unlocking SARS-CoV-2 detection in low- and middle-
1117 income countries. Cell Rep Methods. 2021 Oct 21;1(7):100093.
1118 62. Alcántara R, Peñaranda K, Mendoza-Rojas G, Nakamoto JA, Dueñas E, Alvarez
1119 D, et al. UnCovid: A versatile, low-cost, and open-source protocol for SARS-
1120 CoV-2 RNA detection. STAR Protoc. 2021 Dec 17;2(4):100878.
1121 63. Mendoza-Rojas G, Sarabia-Vega V, Sanchez-Castro A, Tello L, Cabrera-Sosa L,
1122 Nakamoto JA, et al. A low-cost and open-source protocol to produce key enzymes
1123 for molecular detection assays. STAR Protoc. 2021 Nov 1;2(4):100899.
1124 64. Jara M, Adaui V, Valencia BM, Martinez D, Alba M, Castrillon C, et al. Real-
1125 time PCR assay for detection and quantification of *Leishmania* (*Viannia*)
1126 organisms in skin and mucosal lesions: exploratory study of parasite load and
1127 clinical parameters. J Clin Microbiol. 2013 Jun;51(6):1826-33.
1128 65. Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3
1129 real time PCR assay. J Virol Methods. 2001 Feb;91(2):109-17.

1130 66. MedCalc Software Ltd. Diagnostic test evaluation calculator. Available from:
1131 https://www.medcalc.org/calc/diagnostic_test.php (Version 23.0.1; accessed
1132 August 21, 2024)
1133 67. Parida M, Sannarangaiah S, Dash PK, Rao PV, Morita K. Loop mediated
1134 isothermal amplification (LAMP): a new generation of innovative gene
1135 amplification technique; perspectives in clinical diagnosis of infectious diseases.
1136 Rev Med Virol. 2008 Nov-Dec;18(6):407-21.
1137 68. Lopez M, Inga R, Cangalaya M, Echevarria J, Llanos-Cuentas A, Orrego C, et al.
1138 Diagnosis of *Leishmania* using the polymerase chain reaction: a simplified
1139 procedure for field work. Am J Trop Med Hyg. 1993 Sep;49(3):348-56.
1140 69. World Health Organization. Ending the neglect to attain the sustainable
1141 development goals: a road map for neglected tropical diseases 2021–2030. World
1142 Health Organization. 2020. Available from:
1143 https://iris.who.int/handle/10665/338565.
1144 70. Gow I, Smith NC, Stark D, Ellis J. Laboratory diagnostics for human *Leishmania*
1145 infections: a polymerase chain reaction-focussed review of detection and
1146 identification methods. Parasit Vectors. 2022 Nov 5;15(1):412.
1147 71. Gow I, Smith N, Stark D, Ellis J. Molecular Detection of Neglected Tropical
1148 Diseases: The Case for Automated Near-Point-of-Care Diagnosis of
1149 Leishmaniasis. Am J Trop Med Hyg. 2022 Nov 30;108(1):2-6.
1150 72. Deborggraeve S, Laurent T, Espinosa D, Van der Auwera G, Mbuchi M, Wasunna
1151 M, et al. A simplified and standardized polymerase chain reaction format for the
1152 diagnosis of leishmaniasis. J Infect Dis. 2008 Nov 15;198(10):1565-72.
1153 73. Carson C, Quinnell RJ, Holden J, Garcez LM, Deborggraeve S, Courtenay O.
1154 Comparison of *Leishmania* OligoC-TesT PCR with conventional and real-time

1155 PCR for Diagnosis of canine *Leishmania* infection. J Clin Microbiol. 2010
1156 Sep;48(9):3325-30.
1157 74. van Dijk NJ, Hagos DG, Huggins DM, Carrillo E, Ajala S, Chicharro C, et al.
1158 Simplified molecular diagnosis of visceral leishmaniasis: Laboratory evaluation
1159 of miniature direct-on-blood PCR nucleic acid lateral flow immunoassay. PLoS
1160 Negl Trop Dis. 2024 May 7;18(5):e0011637.
1161 75. Dixit KK, Verma S, Singh OP, Singh D, Singh AP, Gupta R, et al. Validation of
1162 SYBR green I based closed tube loop mediated isothermal amplification (LAMP)
1163 assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of
1164 visceral leishmaniasis (VL). PLoS Negl Trop Dis. 2018 Nov 15;12(11):e0006922.
1165 76. Ibarra-Meneses AV, Cruz I, Chicharro C, Sánchez C, Biéler S, Broger T, et al.
1166 Evaluation of fluorimetry and direct visualization to interpret results of a loop-
1167 mediated isothermal amplification kit to detect *Leishmania* DNA. Parasit Vectors.
1168 2018 Apr 17;11(1):250.
1169 77. Puri M, Brar HK, Mittal N, Madan E, Srinivasan R, Rawat K, et al. Rapid
1170 diagnosis of *Leishmania* infection with a portable loopmediated isothermal
1171 amplification device. J Biosci. 2021;46(4):92.
1172 78. Travi BL, De los Santos MB, Shelite TR, Santos RP, Rosales LA, Castellanos-
1173 Gonzalez A, et al. Diagnostic Efficacy of Recombinase-Polymerase-
1174 Amplification Coupled with Lateral Flow Strip Reading in Patients with
1175 Cutaneous Leishmaniasis from the Amazonas Rainforest of Perú. Vector Borne
1176 Zoonotic Dis. 2021 Dec;21(12):941-947.
1177 79. Kobialka RM, Ceruti A, Roy M, Roy S, Chowdhury R, Ghosh P, et al. Portable
1178 smartphone-based molecular test for rapid detection of *Leishmania* spp. Infection.
1179 2024 Aug;52(4):1315-1324.

1180 80. Qian X, Xu Q, Lyon CJ, Hu TY. CRISPR for companion diagnostics in low-
1181 resource settings. Lab Chip. 2024 Oct 9;24(20):4717-4740.
1182 81. Martínez DY, Verdonck K, Kaye PM, Adaui V, Polman K, Llanos-Cuentas A, et
1183 al. Tegumentary leishmaniasis and coinfections other than HIV. PLoS Negl Trop
1184 Dis. 2018 Mar 1;12(3):e0006125.
1185 82. Leon W, Fouts DL, Manning J. Sequence arrangement of the 16S and 26S rRNA
1186 genes in the pathogenic haemoflagellate *Leishmania donovani*. Nucleic Acids
1187 Res. 1978 Feb;5(2):491-504.
1188 83. Inga R, De Doncker S, Gomez J, Lopez M, Garcia R, Le Ray D, et al. Relation
1189 between variation in copy number of ribosomal RNA encoding genes and size of
1190 harbouring chromosomes in *Leishmania* of subgenus *Viannia*. Mol Biochem
1191 Parasitol. 1998 May 1;92(2):219-28.
1192 84. Simpson L. The mitochondrial genome of kinetoplastid protozoa: genomic
1193 organization, transcription, replication, and evolution. Annu Rev Microbiol.
1194 1987;41:363-82.
1195 85. Takagi H, Itoh M, Islam MZ, Razzaque A, Ekram AR, Hashighuchi Y, et al.
1196 Sensitive, specific, and rapid detection of *Leishmania donovani* DNA by loop-
1197 mediated isothermal amplification. Am J Trop Med Hyg. 2009 Oct;81(4):578-82.
1198 86. Verma S, Avishek K, Sharma V, Negi NS, Ramesh V, Salotra P. Application of
1199 loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis
1200 of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. Diagn
1201 Microbiol Infect Dis. 2013 Apr;75(4):390-5.
1202 87. Celeste JLL, Caldeira RL, Pires SDF, Silveira KD, Soares RP, de Andrade HM.
1203 Development and evaluation of a loop-mediated isothermal amplification assay

1204 for rapid detection of *Leishmania amazonensis* in skin samples. Exp Parasitol.
1205 2019 Aug;203:23-29.
1206 88. Adams ER, Schoone GJ, Ageed AF, Safi SE, Schallig HD. Development of a
1207 reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for
1208 the sensitive detection of *Leishmania* parasites in clinical samples. Am J Trop
1209 Med Hyg. 2010 Apr;82(4):591-6.
1210 89. Nzelu CO, Gomez EA, Cáceres AG, Sakurai T, Martini-Robles L, Uezato H, et
1211 al. Development of a loop-mediated isothermal amplification method for rapid
1212 mass-screening of sand flies for *Leishmania* infection. Acta Trop. 2014
1213 Apr;132:1-6.
1214 90. Nzelu CO, Cáceres AG, Guerrero-Quincho S, Tineo-Villafuerte E, Rodriquez-
1215 Delfin L, Mimori T, et al. A rapid molecular diagnosis of cutaneous leishmaniasis
1216 by colorimetric malachite green-loop-mediated isothermal amplification (LAMP)
1217 combined with an FTA card as a direct sampling tool. Acta Trop. 2016
1218 Jan;153:116-9.
1219 91. Abbasi I, Kirstein OD, Hailu A, Warburg A. Optimization of loop-mediated
1220 isothermal amplification (LAMP) assays for the detection of *Leishmania* DNA in
1221 human blood samples. Acta Trop. 2016 Oct;162:20-26.
1222 92. Chaouch M, Mhadhbi M, Adams ER, Schoone GJ, Limam S, Gharbi Z, et al.
1223 Development and evaluation of a loop-mediated isothermal amplification assay
1224 for rapid detection of *Leishmania infantum* in canine leishmaniasis based on
1225 cysteine protease B genes. Vet Parasitol. 2013 Nov 15;198(1-2):78-84.
1226 93. Ruang-Areerate T, Sukphattanaudomchoke C, Thita T, Leelayoova S, Piyaraj P,
1227 Mungthin M, et al. Development of loop-mediated isothermal amplification

1228 (LAMP) assay using SYBR safe and gold-nanoparticle probe for detection of
1229 *Leishmania* in HIV patients. Sci Rep. 2021 Jun 9;11(1):12152.
1230 94. Adams ER, Schoone G, Versteeg I, Gomez MA, Diro E, Mori Y, et al.
1231 Development and Evaluation of a Novel Loop-Mediated Isothermal
1232 Amplification Assay for Diagnosis of Cutaneous and Visceral Leishmaniasis. J
1233 Clin Microbiol. 2018 Jun 25;56(7):e00386-18.
1234 95. Mukhtar M, Ali SS, Boshara SA, Albertini A, Monnerat S, Bessell P, et al.
1235 Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in
1236 Sudan using loop-mediated isothermal amplification (LAMP). PLoS Negl Trop
1237 Dis. 2018 Feb 14;12(2):e0006264.
1238 96. Hossain F, Picado A, Owen SI, Ghosh P, Chowdhury R, Maruf S, et al. Evaluation
1239 of Loopamp™ *Leishmania* Detection Kit and *Leishmania* Antigen ELISA for
1240 Post-Elimination Detection and Management of Visceral Leishmaniasis in
1241 Bangladesh. Front Cell Infect Microbiol. 2021 Apr 26;11:670759.
1242 97. Vink MMT, Nahzat SM, Rahimi H, Buhler C, Ahmadi BA, Nader M, et al.
1243 Evaluation of point-of-care tests for cutaneous leishmaniasis diagnosis in Kabul,
1244 Afghanistan. EBioMedicine. 2018 Nov;37:453-460.
1245 98. Schallig HDFH, Hu RVP, Kent AD, van Loenen M, Menting S, Picado A, et al.
1246 Evaluation of point of care tests for the diagnosis of cutaneous leishmaniasis in
1247 Suriname. BMC Infect Dis. 2019 Jan 7;19(1):25.
1248 99. Ghosh P, Chowdhury R, Maruf S, Picado A, Hossain F, Owen SI, et al. Gauging
1249 the skin resident *Leishmania* parasites through a loop mediated isothermal
1250 amplification (LAMP) assay in post-kala-azar dermal leishmaniasis. Sci Rep.
1251 2022 Oct 27;12(1):18069.

1252 100. Taye B, Melkamu R, Tajebe F, Ibarra-Meneses AV, Adane D, Atnafu S,
1253 et al. Evaluation of Loopamp *Leishmania* detection kit for the diagnosis of
1254 cutaneous leishmaniasis in Ethiopia. Parasit Vectors. 2024 Oct 15;17(1):431.
1255 101. Peng R, Yuqing F, Wiggins TJ, Bahadori N, Rogers JS, Waitkus J, et al.
1256 Multiple-Channel Funnel Adapted Sensing Tube (MFAST) for the Simple and
1257 Duplex Detection of Parasites. ACS Sens. 2025 Apr 25;10(4):2678-2688.
1258 102. Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for the
1259 developing world. Nat Rev Microbiol. 2004 Mar;2(3):231-40.
1260 103. Land KJ, Boeras DI, Chen XS, Ramsay AR, Peeling RW. REASSURED
1261 diagnostics to inform disease control strategies, strengthen health systems and
1262 improve patient outcomes. Nat Microbiol. 2019 Jan;4(1):46-54.
1263 104. Dineva MA, MahiLum-Tapay L, Lee H. Sample preparation: a challenge
1264 in the development of point-of-care nucleic acid-based assays for resource-limited
1265 settings. Analyst. 2007 Dec;132(12):1193-9.
1266 105. Gunaratna G, Manamperi A, Böhlken-Fascher S, Wickremasinge R,
1267 Gunawardena K, Yapa B, et al. Evaluation of rapid extraction and isothermal
1268 amplification techniques for the detection of *Leishmania donovani* DNA from
1269 skin lesions of suspected cases at the point of need in Sri Lanka. Parasit Vectors.
1270 2018 Dec 22;11(1):665.
1271 106. Nguyen LT, Rananaware SR, Pizzano BLM, Stone BT, Jain PK. Clinical
1272 validation of engineered CRISPR/Cas12a for rapid SARS-CoV-2 detection.
1273 Commun Med (Lond). 2022 Jan 12;2:7.
1274 107. Mondal D, Ghosh P, Khan MA, Hossain F, Böhlken-Fascher S,
1275 Matlashewski G, et al. Mobile suitcase laboratory for rapid detection of

1276 *Leishmania donovani* using recombinase polymerase amplification assay. Parasit
1277 Vectors. 2016 May 13;9(1):281.
1278 108. Ghosh P, Sharma A, Bhattarai NR, Abhishek K, Nisansala T, Kumar A, et
1279 al. A Multi-Country, Single-Blinded, Phase 2 Study to Evaluate a Point-of-Need
1280 System for Rapid Detection of Leishmaniasis and Its Implementation in Endemic
1281 Settings. Microorganisms. 2021 Mar 12;9(3):588.
1282 109. Milenia Biotec GmbH. A short guide for improved readout performance.
1283 Available from: https://www.milenia-biotec.com/uploads/2019/07/improved-
1284 CRISPR-readout_final-1.pdf

1285

1286 ## Supporting information captions

1287 **S1 Fig. Multiple sequence alignment of representative kDNA minicircle sequences**
1288 **from members of the *L.* (*Viannia*) and *L.* (*Leishmania*) subgenera, with LAMP**
1289 **primer binding regions and crRNA target site highlighted.** A total of 24 *L.* (*Viannia*)
1290 and 35 *L.* (*Leishmania*) sequences were aligned using Clustal Omega (alignments were
1291 performed separately for each subgenus) and visualized in Jalview v2.11.4.1. The
1292 locations of primer binding regions as well as of the crRNA target site and PAM sequence
1293 in the target DNA are highlighted with colors to indicate sequence conservation within
1294 the *L.* (*Viannia*) subgenus and sequence divergence within the *L.* (*Leishmania*) subgenus.
1295 Nucleotide variants are represented by spaces in the alignment. The kDNA minicircle
1296 sequence from the *L.* (*V.*) *braziliensis* M2904 strain (GenBank accession no.
1297 KY698803.1) exhibited 100% identity across all primer and crRNA target regions. The
1298 sequences shown are from selected representative strains/isolates of a given *Leishmania*
1299 species; additional species and sequences can be examined in the full alignments included
1300 in the S1 File. Figure created with BioRender.com.

1301 **S2 Fig. Multiple sequence alignment of representative 18S rDNA sequences from**
1302 **members of the *Leishmania* and *Trypanosoma* genera, with LAMP primer binding**
1303 **regions and crRNA target site highlighted.** A total of 31 sequences (16 from
1304 *Leishmania* spp. and 15 from *Trypanosoma* spp.) were aligned using Clustal Omega and
1305 visualized in Jalview v2.11.4.1. Primer binding regions as well as the crRNA target site
1306 and PAM sequence in the target DNA are highlighted with colors to indicate sequence
1307 conservation within the *Leishmania* genus and sequence variations within the
1308 *Trypanosoma* genus. Nucleotide variants are represented by spaces in the alignment. The
1309 sequences shown are from selected representative strains/isolates of a given species;
1310 additional species and sequences can be examined in the full alignments included in the
1311 S2 File. Figure created with BioRender.com.

1312 **S3 Fig. Optimization of the incubation time of the LAMP reaction**. To determine the
1313 minimum necessary incubation time of the LAMP reaction for consistent DNA
1314 amplification, tests were performed at different reaction times for *Leishmania* kDNA (10,
1315 20, 30, and 40 min) and 18S rDNA (10, 30, 40, 50, and 60 min) targets. The number and
1316 text enclosed in a rectangle indicates the LAMP reaction time. The amplification
1317 efficiency was assessed using varying amounts of template DNA (*L. braziliensis* M2904
1318 gDNA), corresponding to approximately 2×10^{2}, 2×10^{-1}, and 2×10^{-3} genome
1319 equivalents. A negative control (NTC) reaction was tested in parallel. Raw fluorescence
1320 signals from Cas12a reactions are shown for kDNA (A-D) and 18S rDNA (G-K) for one
1321 representative technical replicate. Normalized data (fluorescence ratio at $t = 25$ min) from
1322 two technical replicates are shown in panels E (kDNA) and L (18S rDNA). A
1323 fluorescence ratio ≥ 2 is considered detected. Fluorescence measurements in this figure
1324 were taken on the Varioskan LUX plate reader. LAMP reaction products (5 µL each) of
1325 kDNA (F) and 18S rDNA (M) were analyzed by 2% agarose gel electrophoresis ran at

1326 100 V for 1 h using SYBR Gold staining. L, 100 bp DNA ladder (ABclonal). Since space
1327 was tight on the agarose gel images, we had to abbreviate the labels for each lane. For
1328 instance, "10^2" actually represents "2×10^2" as indicated in other panels of this figure.

1329 **S4 Fig. Optimization of CRISPR-based detection assays using a lateral flow readout**.
1330 (A) Design of the Milenia GenLine HybriDetect test strips and readout interpretation.
1331 (Left) In the absence of the specific genetic target, the intact biotin-FAM labeled reporter
1332 molecule flows to the control line (C-line). This is interpreted as a negative test result.
1333 (Right) Upon recognition of the genetic target, the CRISPR RNP complex cleaves the
1334 reporter molecule, which flows to the test line (T-line). The signal intensity of the C-line
1335 is weakened. If cleavage of the reporter molecule is partial, both the C-line and T-line
1336 may appear with comparable intensity. Both scenarios are interpreted as a positive test
1337 result. Figure adapted from [109] and created with BioRender.com. (B-F) Different
1338 parameters influencing the LFA readout performance were evaluated to achieve
1339 consistent results: reporter concentration (B), assay buffer (C), incubation temperature
1340 (D) and reaction time (E) of the Cas12a assay, and the concentration of PEG-8000 (F).
1341 Results shown here correspond to the kDNA LAMP-CRISPR assay.

1342 **S5 Fig. Workflow from sample preparation to LAMP-CRISPR assays for analytical**
1343 **specificity testing**. Figure created with BioRender.com.

1344 **S6 Fig. Results of LAMP-CRISPR detection with fluorescence readout in a group of**
1345 **clinical samples**. Raw fluorescence curves generated by Cas12a detection of LAMP
1346 amplicons from *Leishmania* kDNA (A) and 18S rDNA (B) targets in a representative
1347 group of clinical samples harboring varying parasite load levels (see S1 Dataset) and ran
1348 in the same assay plate per genomic target. Out of the 8 tested samples shown, 6 showed
1349 robust fluorescence curves indicating the presence of *Leishmania* kDNA molecules
1350 (panel A; samples coded S16, S23, S31, S52, S72, and S75) whereas the 18S rDNA target

1351 was detected in 4 of them (panel B; samples coded S16, S23, S52, and S75). Fluorescence
1352 measurements in this figure were taken on the Synergy H1 plate reader. The respective
1353 LAMP amplicons (5 μL) targeting kDNA (C) or 18S rDNA (D) were analyzed by 2%
1354 agarose gel electrophoresis (100 V, 60 min) using SYBR Gold staining. Controls included
1355 a positive control (PC, 5×10^4 genome equivalents from *L. braziliensis* M2904 gDNA),
1356 a human negative control (HC, human PBMC gDNA), and a no-template control (NTC)
1357 of the LAMP reaction.

1358 **S7 Fig. Results of LAMP-CRISPR detection with LFA readout in a group of clinical**
1359 **samples**. Clinical samples chosen for this pilot testing (n = 8) were categorized according
1360 to the parasite load levels and tested with kDNA and 18S LAMP-CRISPR assays. Lateral
1361 flow testing was performed on two assay repeats, R1 and R2, per sample. Visualization
1362 on the lateral flow strips (Milenia GenLine HybriDetect strips) was achieved through the
1363 cleavage of the biotin-FAM reporter molecule. Following LFA analysis, the strips were
1364 placed into the cassette housing for image acquisition. C, control line; T, test line.
1365 Controls included DNA samples from two non-leishmaniasis patients (i.e., kDNA qPCR-
1366 negative; samples 09 and C7), a positive control (PC, 2×10^2 genome equivalents from
1367 *L. braziliensis* M2904 gDNA), a human negative control (HC, 20 ng of human PBMC
1368 gDNA), and a no-template control (NTC) of the LAMP reaction.

1369 **S1 Table. Primer and crRNA template sequences used in this study**.

1370 **S1 File. *In silico* alignment of *Leishmania* kDNA minicircle sequences from *Viannia***
1371 **and *Leishmania* subgenera, and location of primer and crRNA binding sites.** This
1372 file contains sequence alignments and visualizations used to assess the *in silico* specificity
1373 of the designed LAMP primers and Cas12a crRNA within conserved regions of
1374 *Leishmania* kDNA minicircles. A total of 1,060 aligned sequences from strains/isolates
1375 belonging to the *L.* (*Viannia*) subgenus and 965 aligned sequences from strains/isolates

of the *L*. (*Leishmania*) subgenus were included. Primer and crRNA binding regions were manually annotated using Jalview v2.11.4.1 to enhance visualization and facilitate identification of conserved target sites. Additionally, a subset of representative sequences, 24 *L*. (*Viannia*) and 35 *L*. (*Leishmania*), is provided in separate alignment project files to illustrate kDNA minicircle sequence conservation and divergence across the two subgenera (see also S1 Fig).

S2 File. *In silico* alignment of 18S rDNA sequences from *Leishmania* and *Trypanosoma* genera, and location of primer and crRNA binding sites. This file contains the alignments and visualizations used to evaluate the *in silico* specificity of the designed LAMP primers and Cas12a crRNA targeting the 18S rDNA. It includes 37 aligned sequences of *Leishmania* spp. and 272 of *Trypanosoma* spp. Primer and crRNA binding regions were manually annotated using Jalview v2.11.4.1 to enhance visualization and identification. Additionally, an alignment of a subset of 31 representative sequences (16 *Leishmania*, 15 *Trypanosoma*) is provided for visualization of 18S rDNA sequence conservation and divergence across the two genera (see also S2 Fig).

S1 Dataset. Excel file containing the data on tested clinical samples generated during the current study. This file contains the LAMP-CRISPR and qPCR data on tested clinical samples, as well as the determination of threshold cutoff values for fluorescence-based CRISPR-Cas12a assay result interpretation.

Author Contributions

Conceptualization: Vanessa Adaui.

Formal analysis: Eva Dueñas, Percy Huaihua, Vanessa Adaui.

Funding acquisition: Vanessa Adaui.

Investigation: Eva Dueñas, Ingrid Tirado, Percy Huaihua, Ariana Parra del Riego, Luis Cabrera-Sosa, Jose A. Nakamoto, Carlos M. Restrepo.

Project administration: Vanessa Adaui.

Resources: Luis Cabrera-Sosa, Jose A. Nakamoto, María Cruz, Carlos M. Restrepo, Jorge Arévalo, Vanessa Adaui.

Supervision: Vanessa Adaui, Jorge Arévalo.

Visualization: Eva Dueñas, Ingrid Tirado.

Writing – original draft: Eva Dueñas, Ariana Parra del Riego, Vanessa Adaui.

Writing – review & editing: Eva Dueñas, Ingrid Tirado, Percy Huaihua, Ariana Parra del Riego, Luis Cabrera-Sosa, Jose A. Nakamoto, María Cruz, Carlos M. Restrepo, Jorge Arévalo, Vanessa Adaui.

Acknowledgments

We thank Pohl Milón (Universidad Peruana de Ciencias Aplicadas) for inspiring discussions; Yomara Romero (Universidad Peruana de Ciencias Aplicadas) for assistance with sequence alignments and advice on their presentation; Edith Málaga and Manuela Verástegui (Universidad Peruana Cayetano Heredia) for providing genomic DNA from the *Trypanosoma cruzi* strains tested here; and the Office of Research at the Universidad Peruana de Ciencias Aplicadas for the support provided to carry out this research work.

Funding Statement

This work was supported by ProCiencia, the Peruvian National Council for Science, Technology, and Technological Innovation (CONCYTEC) - The World Bank (contract 036-2019-FONDECYT-BM-INC.INV) and by the Universidad Peruana de Ciencias Aplicadas (internal fund C-005-2024). I.T. was supported by a postgraduate scholarship

of ProCiencia (contract PE501084865-2023). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


kDNA
Skin ulcer
18S rDNA
Biopsy
Swab
Filter paper
DNA extraction
LAMP products
Immersion oil
Bst DNA pol
LAMP primers
65°C for 30-50 min
LAMP amplification
Cas12a
crRNA
Reporter
25°C for 25 min
CRISPR/Cas12a detection
i.Lateral flow strips (LFA)
Fluorescence (RFU)
Detected
Non detected
Time (min)
+
-
ii.Fluorescence signal
Readout

Figure


DNA target
A
B
C
D
E
Bst-LF, 65 °C
"strand displacement"
18S crRNA target sequence:
5' TGACTCAATTCATTCCGTGCGAAA 3'
kDNA-crRNA target sequence:
5' TGGCATACAGAAACCCCGTTCAAA 3'
Forward and backward external primers:
Forward and backward internal primers:
FIP:
BIP:
Forward and backward loop primers:
crRNA target sequence:
Kinetoplast (kDNA) minicircles
18S rDNA
PAM sequence: 5' VAAA 3'

Figure


A
kDNA Ratio S/NTC
GE/rxn
D
18S rDNA Ratio S/NTC
GE/rxn
B
Genome equivalents per reaction
NTC
T
C
E
Genome equivalents per reaction
NTC
T
C
C
kDNA LAMP products
bp
GE
L
NC
500
300
200
F
18S rDNA LAMP products
bp
GE
L
NC
500
300
200

Figure

A


kDNA
18S rDNA
L.(V.)braziliensis M2904
L.(V.)braziliensis M2903
L.(V.)braziliensis LC2177
L.(V.)braziliensis LC2043
L.(V.)peruviana WR-2771
L.(V.)peruviana HB86
L.(V.)peruviana LCA08
L.(V.)guyanensis M4147
L.(V.)lainsoni M6426
L.(V.)panamensis BD-02
L.(L.)amazonensis M2269
L.(L.)mexicana BEL21
L.(L.)aristidesi GML
L.(L.)major WR-1088
L.(L.)donovani WR-2801
L.(L.)infantum P142
T.cruzi Tulahuen
T.cruzi VT-1
T.cruzi Sylvio X10
M.tuberculosis PA155-18C
P.falciparum HB3
Human control
2 3
2 3

B


Human control
NTC
Lbra M2904
Lguy M4147
Lper LCA08
Mt PA155-18C
Pf HB3
Tc Tulahuen
Tc Sylvio X10
Tc VT-1
1 2 3 4 5 6 7 8 9 10
T
C
T
C
Negative controls
Positive controls
Non-related microbes
T. cruzi strains

Figure



Figure


A
B
C
D
Ratio S/NTC
kDNA-Cq
Parasite Load
1.46 (kDNA)
1.30 (18S rDNA)
0
2
4
6
10
20
30
40
10^{-1}
10^{0}
10^{1}
10^{2}
10^{3}
10^{4}
10^{5}
10^{6}
10^{7}

Figure


A
100
80
60
40
20
0
Sensitivity (%)
0
20
40
60
80
100
100 - Specificity (%)
AUC 0·9732
(95% CI 0·9456–1·0000);
p<0.0001
B
100
80
60
40
20
0
Sensitivity (%)
0
20
40
60
80
100
100 - Specificity (%)
AUC 0·8764
(95% CI 0·8033–0·9494);
p<0.0001

Figure


Parasite load levels
High
Intermediate
Low
kDNA
T
C
25 75 21 16 51 76 19 20 07 23 53 47 12 31 35 52 03 05
LFA readout: + + + + + + + + + + + + + + + + - -
RFU readout: + + + + + + + + + + + + + + + + - -
Cq: 10.74 12.13 16.82 17.90 17.96 18.36 20.76 21.26 24.38 25.91 25.97 27.30 27.56 27.57 28.76 28.89 29.74 33.88
18S
T
C
25 75 21 16 51 76 19 20 07 23 53 47 12 31 35 52 03 05
LFA readout: + + + + + + + + + + + - - - + + - -
RFU readout: + + + + + + + + + + + - + - + + - -
Controls
kDNA
T
C
09 C7 PC HC NTC
18S
T
C
09 C7 PC HC NTC

Figure